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ABSTRACT
Sphingosine kinase enzymes (SK1 and SK2) catalyse the conversion of sphingosine into 
sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of 
isoform amino acid sequence differences for SK2 onto the recently available crystal structures of 
SK1 suggests that subtle structural differences exist in the foot of the lipid-binding ‘J-channel’ in 
SK2, the structure of which has yet to be defined by structural biology techniques. We have probed 
these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-
543. Here we show how it is possible, even with relatively conservative changes in compound 
structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective 
inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with 
retention of nanomolar potency.
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INTRODUCTION
Sphingosine 1-phosphate (S1P) is a key signalling lipid derived from sphingosine (Sph) by the 
action of sphingosine kinases (SK1 and SK2). S1P is transported to the extracellular environment, 
where it functions as a ligand for a family of five S1P-specific G protein coupled receptors (S1P1-5), 
but it also acts on specific intracellular target proteins, such as histone deacetylases 1/2 
(HDAC1/2).1, 2 Irreversible cleavage of S1P is catalysed by S1P lyase, producing (E)-2-
hexadecenal and phosphoethanolamine,3 but S1P is also reversibly dephosphorylated by S1P 
phosphatase to regenerate Sph,4-6 levels of which are additionally influenced by flux through the 
ceramide (Cer) synthesis pathway.7 The effects of S1P on cell function favour proliferation, 
migration, differentiation and survival and are generally opposed by Cer, which induces apoptosis, 
senescence and growth arrest.8, 9 As a consequence the concept of the ‘sphingolipid rheostat’ was 
proposed,10, 11 in which the inter-conversion of Cer via Sph to S1P controls cellular fate (recently 
reviewed12, 13). Altered S1P signalling has been associated with numerous pathophysiologies, 
including cancer, cardiovascular disease, neurodegenerative conditions, diabetes and 
inflammatory disease.14 The possibility of manipulating the sphingolipid rheostat for therapeutic 
purposes has therefore provided a rationale for exploring the development of SK inhibitors and 
their potential to reduce S1P formation and signalling and to raise pro-apoptotic Cer levels. 
The SK1 and SK2 enzymes are encoded by distinct genes and differ in their subcellular 
localisation, biochemical properties and functions; there are three N-terminal variants of SK1 and 
two N-terminal variants of SK2.15, 16 A number of classes of SK inhibitors have emerged in the 
last two decades, including the recent discovery of an ATP-competitive SK inhibitor chemotype 
that decreases cellular S1P levels, elevates Sph/Cer, induces apoptosis, and that inhibits cell 
proliferation and colony formation.17 Most work to date, however, has focused on the development 
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of Sph-competitive inhibitors. This includes the development of inhibitors selective for SK1 that 
exhibit nanomolar potency, such as PF-543 (1),18 Genzyme-51 (2)19 and Amgen-23 (3),20 Chart 1. 
PF-543 reduces sickling of red blood cells21 in vitro and in vivo and attenuates post-infarction 
cardiac remodeling.22 We have also demonstrated23 that PF-543 protects against cardiomyocyte 
apoptosis and reduces cardiac maladaptive hypertrophy in a mouse model of pulmonary 
hypertension.
Page 3 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Chart 1. Lipid substrate (Sph), product (S1P) and established inhibitors for SK1 and SK2.
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Early prototype Sph-competitive SK2-selective inhibitors include ABC294640 (4),24 K145 
(5),25 SLR0808110 (6)26 and (R)-FTY720 methyl ether (ROMe; 7),27 Chart 1. Of these compounds, 
ABC294640, which induces cell death via apoptotic and autophagic pathways,24,28 has been tested 
in several disease models for cancer,24 rheumatoid arthritis29 and ulcerative colitis.30 The 
compound has proceeded to phase I/II clinical studies targeting multiple oncology and 
inflammatory indications. However, ABC294640 also indirectly targets dihydroceramide 
desaturase and induces the proteasomal degradation of SK1 in prostate cancer cells and in 
HEK293T cells.31-33 ROMe, an SK2-selective inhibitor (Ki 14 μM) with no activity against SK1 at 
100 μM, inhibits DNA synthesis in breast cancer cells and induces autophagic death of T-cell acute 
lymphoblastic leukemic cells.27, 34 Very recently two reports have disclosed examples of more 
potent SK inhibitors, Pfizer-27c (8)35 and VT-20dd (9),36 with selectivity for SK2. Despite these 
developments and a growing interest in the (patho)physiological roles of SK2, a clear structural 
rationale for the development of high potency SK2-specific inhibitors has yet to emerge. 
No SK2 crystal structures are available as yet to support structure-based design of SK2-
selective inhibitors, but amino acid sequence alignment suggests a high degree of homology to 
SK1, the structure of which has recently been solved by X-ray crystallography.37,20,38 SK1 exhibits 
a bidomain architecture comprising an ATP-binding N-terminal domain (NTD) and a C-terminal 
domain (CTD) that hosts the Sph binding site, Figure 1. The CTD folds as a two-layer β-sandwich 
with three extended inter-strand loops packing across one face to generate the Sph binding site as 
a J-shaped cavity, termed the ‘J-channel’. One of the three ‘lipid binding loops’, LBL-1, consists 
of two reverse-paired helices (α7 and α8) that may gate substrate entry and product egress by a 
hinged motion.39 Residues in LBL-1 and in the second loop, LBL-2, define much of the contact 
surface for the polar head group and central region of the lipid. The third loop, LBL-3, folds with 
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an additional helix (α9), running antiparallel along α8, and provides enclosure for the lipid tail. To 
date, SK1 co-crystal structures have been acquired with three inhibitors bound in the J-channel, 
namely with SKi (10; also known as SKI-II),37 with Amgen-23 (3),20 and most recently with PF-
543 (1).38 We have used the latter structure as a starting point to explore differences in the foot of 
the J-channel of SK1 and SK2. Here we report our results from a ligand-based structure activity 
relationship (SAR) study that highlights key determinants for switching between SK1-selective 
and SK2-selective inhibition.
Figure 1. The structure of SK1 is shown with bound PF-543 (1; orange surface) (PDB: 4V24).38 
PF-543 occupies the substrate Sph binding site, formed by the packing of three lipid binding loops 
(LBL-1 to LBL-3) against a β -sandwich core. The nucleotide binding site is shown by 
superimposition of Mg-ADP (green sphere/rose surface) from its separate co-crystal structure 
(3VZD) with SK1.37
Page 6 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
RESULTS AND DISCUSSION
Design rationale for ligand selectivity switching. Of the 20 or so residues that contribute to the 
J-channel in SK1, SK2 differs at only 3 points in the direct hydrophobic contact surface of the 
binding site—namely in Ile174, Met272 and Phe288 of SK1, corresponding respectively to 
Val304, Leu517 and Cys533 in SK2 (Figure 2, orange). Phe288 stoppers the toe of the SK1 J-
channel, and its substitution by Cys533 in SK2 may result in a longer J-channel and potentially 
also confer greater surface plasticity in that region of SK2 due to loosened packing against adjacent 
hydrophobic residues. Ile174 and Met272 contribute to the throat of the J-channel and, in the 
SK1/PF-543 co-crystal structure, are seen to form part of the flanking surface on either side of the 
inhibitor’s p-xylylene subunit; their replacement by Val and Leu may make this region of the J-
channel slightly wider in SK2 than in SK1. Ile174 additionally contributes surface on one edge of 
the PF-543 terminal subunit, with contact distances of 3.6 and 3.4 Å between its Cδ methyl carbon 
and the PF-543 phenyl ortho and meta carbons respectively. A leucine (Leu261; Figure 2, yellow), 
that is packed against Ile174 in SK1, also contributes to the contact surface around the edge of the 
PF-543 terminal phenyl and, although conserved in SK2 (as Leu506), may differ in its 
conformational profile due to the replacement of the adjacent Ile174 in SK1 by Val304 in SK2. 
Together, these considerations suggest that the J-channel toe might be expanded in SK2 on a 
contact surface mapping to the para-position of the terminal phenyl of SK1-bound PF-543 (Figure 
2, green arrow).
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Figure 2. J-channel surface detail (mesh) from the PF-543/SK1 co-crystal (PDB: 4V24),38 
highlighting key isoform residue differences that likely impact on the J-channel structure of SK2. 
SK1 residue numbering is shown; cognate SK2 residues, where different, are in parenthesis. 
(Residue color notation: see text.)
In principle, an expanded surface in SK2 at the J-channel toe might contribute to reduced 
affinity for PF-543 and hence, at least in part, to the established SK1-over-SK2 selectivity of this 
inhibitor (Chart 1). However, SK2 also differs from SK1 in several other residues that, whilst not 
contributing directly to the ligand contact surface, are likely to indirectly affect the J-channel 
structure. Thus, a set of residues in LBL-3 of SK1 (Val294, Met298, Met312, Tyr314, Tyr318; 
Figure 2, green) differs in SK2 (as Ile539, Ala543, Phe557, Leu559 and Gln563 respectively). 
Inspection of the SK1/PF-543 co-crystal structure suggests that these differences may impact on 
the conformation of a conserved leucine (Leu302 in SK1; Figure 2, magenta), which contributes 
to the contact surface for the sulfonyl group of PF-543. We hypothesized that the cognate residue 
(Leu547) in SK2 might be driven inwards to narrow the J-channel at that point. If so, surface 
encroachment in the J-channel heel of SK2 might then interdict comfortable accommodation of 
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the sulfonyl oxygens of PF-543 and also contribute to the observed SK1-selectivity of this 
inhibitor.
Two further residue differences, Ala175 and Ala339 in SK1 (corresponding to Ser305 and 
Thr584 in SK2), might also potentially be relevant to isoform discrimination by ligands targeting 
the J-channel. These residues (Figure 2, cyan) lie proximal to the 2-(hydroxymethyl)pyrrolidine 
‘head group’ of PF-543, and their variation in SK2 might affect a network of polar interactions 
that engages the PF-543 head group or/and slightly reposition LBL-1 with respect to the β -
sandwich core, which could then impact on the surface of a notch in the J-channel that 
accommodates the PF-543 methyl group (Figure 2). However, it is known38 that the hydroxyl 
group of SK1-bound PF-543 precisely maps to the position of the Sph-3-OH and, given that Sph 
serves as a substrate for both SK1 and SK2, it is likely that the ‘head group’ hydrogen bonding 
features in SK2 should also support the binding of the PF-543 2-(hydroxymethyl)pyrrolidine 
subunit. Thus, in seeking to identify determinants for SK2-selective inhibition, we focused 
attention on a series of PF-543 analogues that retained the 2-(hydroxymethyl)pyrrolidine head 
group but embodied alterations to the tail targeted to the enclosed J-channel foot, predicted by our 
analysis to offer scope for isoform-discriminating interactions with ligands. Accordingly, we 
prepared a concise compound test set to evaluate whether SK2-inhibitory activity might be 
enhanced by alleviating steric demand in the sulfonyl linker and/or by deletion of the PF-543 
methyl group. We also sought to test the hypothesis that optimisation of ligand fit to the J-channel 
toe in SK2 might confer selectivity over SK1.
Synthesis of probe compound set. In order to assess the contribution of the methyl group 
to the SK1 selectivity of PF-543, we prepared the normethyl analogue (18; Scheme 1) for 
evaluation. The compound was prepared from m-methoxybenzyl bromide (11) by reaction with 
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sodium benzenesulfinate followed by boron tribromide mediated cleavage of the aryl methyl ether 
in 12 to afford phenol 14. The latter was then alkylated with 4-(bromomethyl)benzaldehyde and 
the resulting aldehyde (16) subjected to reductive amination with (R)-(–)-prolinol.
Scheme 1. Synthesis of probe compounds 18 and 19.a
Y = CH2
Y = O
18
19
(71% from 16)
(33% from 17)
Ph
S
Y OH
Ph
S
Y O
N
OH
HO OH
Ph
S
Y O
CHO
O O
O O
O O
13
Y = CH2
Y = O
14
15
(77% from 12)
(21% from 13)
Y = CH2
Y = O
16
17
(81% from 14)
(88% from 15)
(a)
(d)
Ph
S
OMe
O O
Br
OMe
(c)
11 12
(b)
(e)
aReagents and conditions: (a) NaSO2Ph, Aliquat® 336, 85 °C (47%); (b) BBr3, CH2Cl2, –78 °C 
(77%); (c) phenylsulfonyl chloride K2CO3 / MeCN (21%); (d) 4-(bromomethyl)benzaldehyde, 
K2CO3, MeCN, 60 °C; (e) (R)-2-(hydroxymethyl)pyrrolidine, NaBH(OAc)3, DCE.
A collection of compounds was then prepared in order to evaluate the contribution of the 
–SO2-CH2– tail linker to inhibitory performance and selectivity. Analogues were designed to test 
the impact of replacing the PF-543 sulfonyl group by methylene, but we also included an isosteric 
sulfonate (19) to probe the impact of subtle changes in ligand bond angle preferences. Sulfonate 
19 was prepared by initial sulfonylation of resorcinol (13) followed by alkylation of the resulting 
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phenol (15) with 4-(bromomethyl)benzaldehyde and reductive amination with (R)-(–)-prolinol, 
Scheme 1. 
The ethylene-linked analogue (23, Scheme 2) was prepared to assess the impact of reducing 
steric demand in the locus occupied by the PF-543 sulfonyl group. For reasons of synthetic 
convenience, this and other sulfonyl deletion analogues were prepared for comparative evaluation 
against 18 without the methyl group in place on the central arene ring. Synthesis of 23 was 
undertaken from acetylene 20, prepared by ambient temperature Sonogashira coupling of 3-
iodophenol40 with phenylacetylene. The acetylene was hydrogenated to afford phenol 21, which 
was alkylated with 4-(bromomethyl)benzaldehyde to afford 22. Reductive amination of the latter 
with (R)-(–)-prolinol afforded 23.
Scheme 2. Synthesis of probe compound 23.a
OH
Ph
O
CHO
O
N
OH
(a)
(b)
20 21
(c)
22
23
OH
aReagents and conditions: (a) H2, Pd/C, EtOH (95%); (b) 4-(bromomethyl)benzaldehyde, K2CO3, 
MeCN, 20 °C, 16 h (87%); (c) (R)-2-(hydroxymethyl)pyrrolidine, NaBH(OAc)3, DCE (82%).
An ether-linked variant (49) of 23 was prepared according to Scheme 3. Thus, resorcinol 
(13) was alkylated with benzyl bromide and the resulting phenol (25) transformed into 49 by the 
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two-step alkylation/reductive amination procedure applied in Schemes 1 and 2 for compounds 18, 
19 and 23. A subset of six halogenated analogues (50–55, Scheme 3) was then expanded to 
facilitate systematic exploration of the space in the J-channel foot. Two further analogues were 
included in the ether-linked test set to explore the impact of steric demand in the critical toe region 
of the J-channel––namely, methyl ether 56 and nitrile 57, with bent and linear two-atom extensions 
from the para-position of the tail arene. The sulfide counterpart (58) of the ether-linked parent (49) 
was prepared in a similar manner starting from benzenethiol (24). The para-fluorophenyl and 
para-chlorophenyl analogues (59 and 60) of this latter compound were made by a similar strategy. 
Sulfides 58–60 were included to test the impact of incorporating a heteroatom in the linker with 
greater steric demand and differing bond angle preferences, which might impact on positioning of 
the ligand’s terminal para-site in the critical J-channel toe region.
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Scheme 3. Synthesis of probe compounds 49–60.a
Y OH
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N
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Y = S
Y = S
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33
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36
X = H
X = o-F
X = m-F
X = p-F
X = o-Cl
X = m-Cl
X = p-Cl
X = p-OMe
X = p-CN
X = H
X = p-F
X = p-Cl
(55% from 13)
(53% from 13)
(58% from 13)
(38% from 13)
(54% from 13)
(49% from 13)
(48% from 13)
(32% from 13)
(47% from 13)
(68% from 24)
(71% from 24)
(79% from 24)
(a) or (b)
(c) or (d)
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = S
Y = S
Y = S
37
38
39
40
41
42
43
44
45
46
47
48
X = H
X = o-F
X = m-F
X = p-F
X = o-Cl
X = m-Cl
X = p-Cl
X = p-OMe
X = p-CN
X = H
X = p-F
X = p-Cl
(88% from 25)
(62% from 26)
(64% from 27)
(77% from 28)
(71% from 29)
(55% from 30)
(96% from 31)
(68% from 32)
(95% from 33)
(79% from 34)
(93% from 35)
(84% from 36)
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = O
Y = S
Y = S
Y = S
49
50
51
52
53
54
55
56
57
58
59
60
X = H
X = o-F
X = m-F
X = p-F
X = o-Cl
X = m-Cl
X = p-Cl
X = p-OMe
X = p-CN
X = H
X = p-F
X = p-Cl
(70% from 37)
(69% from 38)
(57% from 39)
(73% from 40)
(58% from 41)
(50% from 42)
(86% from 43)
(84% from 44)
(38% from 45)
(95% from 46)
(78% from 47)
(53% from 48)
m
op
(e)
aReagents and conditions: (a) 25–33: (substituted)benzyl bromide (or 4-chlorobenzyl chloride in 
the case of 31), K2CO3, acetone, 65 °C, 5 h; (b) 34–36: (substituted)benzyl bromide (or 4-
chlorobenzyl chloride in the case of 36), K2CO3, MeCN, 20 °C, 16 h; (c) 37–45: NaH, DMF, then 
4-(bromomethyl)benzaldehyde, 16 h, 20 °C; (d) 46–48: 4-(bromomethyl)benzaldehyde, K2CO3, 
MeCN, 20 °C, 16 h; (e) (R)-2-(hydroxymethyl)pyrrolidine, NaBH(OAc)3, THF (for 49–57) or 
DCE (for 48–60).
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SK-inhibitory performance and selectivity of probe compound set. Compounds were 
evaluated for inhibition of purified SK1 and SK2 using a radiometric assay, as detailed in our 
earlier work.41 In brief, the procedure uses [ γ -32P]ATP and measures incorporation of the 
radiolabelled phosphate into the S1P product. SK1 and SK2 were assayed, respectively, at 3 and 
10 µM Sph substrate concentration. These concentrations correspond to the Km values of SK142-44 
and SK227 and, therefore, allow direct comparison of the sensitivity of the two enzymes at 50% 
saturation with Sph. Assays were performed with ATP at 250 µM concentration, well above the 
Km value for the nucleotide, to ensure saturation with ATP. Activity data are summarised in Chart 
2.
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Chart 2. SK1 and SK2 inhibitory activity for probe compound set derived from PF-543 (1).a
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39
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26
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41
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methylenesulfanyl
X
o
p
m
X = H
X = p-F
X = p-Cl
58
59
60
137
765
2,360‡
26
17
31
0.88
0.75
0.063
3.5
0.26
0.11
101
>25
>2.7
0.74
0.012
<0.048
–
5.3
45
76
SI
† % enzyme inhibition at 3 µM test concentration
‡ Estimated IC50 from partial concentration response curve (1 nM – 3 µM range)
a SK1 activity was assayed using 3 μM Sph and 250 μM ATP. SK2 activity was assayed using 10 
μM Sph and 250 μM ATP. Data are reported as IC50 values (or % enzyme inhibition) vs control 
determined in triplicate assays. NE: no inhibitory effect at maximal test concentration of 3 µM. SI 
denotes selectivity index as IC50 (SK1) / IC50 (SK2).
We have previously obtained41 an IC50 of 28 nM for inhibition of SK1 by PF-543 in our 
assay, considerably higher than the Ki value of 3.6 nM reported by Schnute et al.18, with the caveat 
that the latter determination was performed under conditions where ATP was not saturating and 
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therefore subject to two-substrate kinetics. As reported, however, PF-543 was highly selective for 
inhibition of SK1, giving only 33% inhibition of SK2 at 5 μM and 72% at 50 μM.
Our analysis (vide supra) suggested that the most likely explanation for the SK1-over-SK2 
selectivity of PF-543 is due to surface encroachment in the SK2 J-channel heel targeted by the 
inhibitor’s sulfonyl group (Figure 2, red arrow). However, at the outset of our studies we could not 
eliminate the possibility that structural differences in the sub-pocket that accommodates the PF-
543 methyl group (Figure 2, ‘notch’) might also be a contributory factor. We therefore evaluated 
the normethyl analogue (18) of PF-543. This compound showed a modest (5-fold) loss in SK1-
inhibitory potency compared to PF-543, consistent with a slight reduction in favourable surface 
contact with that isoform. However, the gain in SK2 inhibition that might have been expected for 
relief of an unfavourable surface compression against the methyl, was not observed. Indeed, only 
slight inhibition of SK2 (16%) was detectable at the maximal test concentration of 3 µM in our 
current studies, suggesting that the PF-543 methyl group is not a strong determinant of selectivity. 
During the course of our studies Schnute et al. disclosed35 further details of their development of 
PF-543, including comparative activity data for normethyl analogue 18 using a different assay 
system. In this study the methyl group was also shown to contribute only marginally to the strong 
SK1-selectivity of PF-543; its deletion led to a change in selectivity by less than a factor of 2.
Interestingly the sulfonate analogue (19) was 13-fold more potent against SK1 than its 
counterpart (18) with the sulfonylmethylene linker. A corresponding increase in inhibitory potency 
was also seen against SK2, with a quantifiable IC50 of 902 nM determined. Replacement of the 
sulfonyl group in 18 with a second methylene in 23 led to a modest 5.5-fold improvement in 
potency against SK1 but a pronounced enhancement in potency against SK2 so that the compound 
was almost equipotent against both isoforms (IC50 26 and 35 nM for SK1 and SK2 respectively). 
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Taken together, these results suggest that the heel of the SK1 J-channel might be a tight fit for the 
sulfonylmethylene linker in PF-543 and 18 and supported our hypothesis that in SK2 the J-channel 
heel may be tighter still, encroaching sufficiently on the sulfonyl oxygens so as to be a key 
determinant for isoform discrimination. Thus, in SK2 higher compression is postulated along a 
trajectory (Axis-1 in Figure 3) between the head group and sulfonyl oxygens of the ligand, with 
the head group locked in place by a highly organised network of polar interactions involving 
features that normally serve to position the substrate for phosphorylation. These ‘headlock’ 
features include a structural water and an aspartic acid on helix-α7 (Asp178 in SK1, conserved as 
Asp308 in SK2) that have been shown to form three tight hydrogen bonds with charge stabilisation 
to the hydroxypyrrolidinium subunit of PF-543 in its SK1 co-crystal structure.38
O
N
O
H
HEEL
TOE
SK1
SK2
Axis-2
A
xis-1
HE
LIX
-9
Compression Axis-2
SK1
SK2
accentuated
relaxed
Compression Axis-1
SK1
SK2
relaxed
accentuated
Phe285
Cys533
Leu302
Leu547
O
O
H
HEAD LOCK
(water)
Figure 3. Key compression axes postulated to influence ligand binding to the J-channels of SK1 
and SK2.
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The methyleneoxy-linked analogue (49) also exhibited near equipotent inhibitory activity 
against the two isoforms, but with a marginal increase in overall potency relative to the ethylene-
linked compound (23). Thus, 49 exhibited IC50 values of 14 and 16 nM against SK1 and SK2 
respectively. However, replacement of the oxygen by a larger sulfur atom in compound 58 caused 
a 10-fold loss in potency against SK1 with only a slight loss (< 2-fold) against SK2, thereby 
resulting in a compound with reversed selectivity (albeit modest) in favour of SK2 (IC50 values of 
137 and 26 nM against SK1 and SK2 respectively). This was an important finding because it 
supported our second hypothesis, namely that the J-channel toe is likely expanded in SK2 or/and 
exhibits greater plasticity. Thus, compression along an axis linking the large sulfur atom and para 
position of the phenyl ring in 58 (Axis-2 in Figure 3) might be less severe in SK2 than in SK1. 
Indeed, analysis of our PF-543/SK1 co-crystal structure38 (Figure 2) had suggested a remarkably 
close fit for the phenylsulfonylmethylene tail unit of PF-543 in the SK1 J-channel, with the para-
CH packed against Phe288 and the methylene of the linker wedged against helix-α9. Conceivably, 
alleviation of compression between these two points (and associated ligand strain) might 
contribute to the enhanced inhibitory potency of sulfonate 19 over the sulfonylmethylene-linked 
analogue (18). 
We next sought to exploit the hypothesised tighter compression axis between toe and heel 
in SK1 (Axis-2 in Figure 3) still further by installation of a substituent in the terminal phenyl ring 
of 49 and 58, with a particular focus on the para-position to see whether compounds with even 
greater selectivity for SK2 could be achieved. Given the potential differences in J-channel surface 
allied to the replacement of Ile174 in SK1 by Val304 in SK2, however, we also wished to examine 
the impact of substitution at the ortho- and meta-positions. For that reason, we evaluated fluorides 
50–52 and chlorides 53–55 derived from methyleneoxy-linked parent 49. The standout feature 
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with this compound set was indeed a pronounced loss in SK1-inhibitory potency for the para-
fluoro and para-chloro analogues (52 and 55), which showed ca. 12-fold and 295-fold increases 
in IC50 relative to 49 respectively. Some loss in potency against SK2 was also observed for these 
compounds (≤ 3-fold relative to parent 49), but SK1 was preferentially penalised, leading to highly 
selective, nanomolar-potent SK2 inhibition in the case of chloride 55 (see concentration response 
curves in Figure 4). Curiously the para-fluoro analogue (52; SK2 IC50 49 nM) showed equivalent 
or even rather more loss in SK2 potency relative to parent 49 (SK2 IC50 16 nM) than its chloride 
counterpart (55; SK2 IC50 41 nM). This outcome may reflect a requirement for some induced fit 
to accommodate the halogen in SK2. Thus, the cost associated with side chain perturbation caused 
by binding of the ligand might be offset by greater surface contact for the chloride over the fluoride.
SK1-selective inhibition SK2-selective inhibitionequipotent SK1/SK2 inhibition
compression along ‘Axis-2’ (Figure 3)compression along ‘Axis-1’ (Figure 3)
log [Compound 60] (M)log [Compound 58] (M)log [Compound 23] (M)
log [Compound 55] (M)log [Compound 52] (M)log [Compound 49] (M)
log [Compound 18] (M)
Figure 4. Selected SK1 and SK2 concentration response curves for PF-543-derived J-channel 
probes, highlighting the reversal of behaviour from SK1-selective inhibition (left) to SK2-selective 
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inhibition (right) with ligand features that induce compression along Axis-1 and Axis-2 of Figure 
3 respectively. (Assay conditions: see legend to Chart 2.)
In the case of the methylenesulfanyl-linked analogue (58), the effects of para-fluoro and 
para-chloro substitution (59/60) broadly mirror those seen in the methyleneoxy-linked series 
(52/55), where inhibition of SK1 but not SK2 is significantly penalised (Chart 2). Although 
differences in the size and bond angle preferences of the sulfide and ether linkages may subtly 
modulate terminal halogen fit to the J-channel toe and ligand strain, in both cases the presence of 
the larger chlorine atom afforded greatest isoform discrimination, with selectivity for inhibition of 
SK2 over SK1 in the range of 75-fold to 100-fold for 60 and 55. Introduction of bulkier or/and 
more polar para-substituents may be counterproductive for SK2 inhibitory performance however. 
Thus, in the methyleneoxy-linked series introduction of a methoxy group (compound 56, SK2 IC50 
119 nM) led to a 7-fold loss in SK2 inhibitory potency relative to parent 49 and a linear nitrile 
extension (compound 57, SK2 IC50 1.12 µM) caused a 70-fold loss in activity. Whilst this fall off 
in inhibitory potency may reflect a limit to the capacity of the SK2 J-channel toe, changes in dipole 
and lipophilicity of the terminal subunit may also be factor in the activity fall off. Thus, a nitrile 
group is sometimes exploited as a bioisostere for the halogen in (hetero)aromatic chlorides, 
conferring a significant reduction in lipophilicity and, therefore, increased lipophilic ligand 
efficiency.45, 46
In contrast to substitution at the para-position, the SK1-inhibitory activity of 49 is more 
tolerant of halogenation at the ortho- and meta-positions on the terminal arene (Chart 2, 
compounds 50, 51, 53 and 54). Here only modest activity loss (ca. 3-fold) is observed (50/53/54), 
whilst meta-fluorination even marginally enhances activity (51, SK1 IC50 9 nM) relative to parent 
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49 (SK1 IC50 14 nM). Interestingly SK2 is less tolerant of substitutions at the ortho- and meta-
positions, particularly at the latter site, where fluorination (51, SK2 IC50 143 nM) and chlorination 
(54, SK2 IC50 412 nM) produce respectively 9-fold and 26-fold activity loss versus parent 49 (SK2 
IC50 16 nM). These results suggest that the SK2 J-channel foot, whilst extended compared to SK1, 
is tighter in width, at least between certain points. 
Structural inferences for the SK2 J-channel. Crystal structures of SK1 have only 
recently emerged (since 2013), whilst no structures are currently available for SK2. To facilitate 
qualitative rationalization of the isoform selectivity profiles of the ligands, we constructed an 
homology model for SK2 based on the crystal structure (4V24) of the large SK1 splice variant 
(SK1b, sometimes also called SK1c) with bound PF-543 that we had recently determined at 1.8 Å 
resolution.38 In brief, an initial model was generated using the default automated routines of the 
SWISS-MODEL server47-50 and this was refined using the Small Molecule Drug Discovery 
software suite from Schrödinger, LLC. In particular, LBL-2 was remodelled from the structure of 
the corresponding loop in the Enterococcus faecalis diacylglycerol kinase family protein, as 
defined in the crystal structure 4WER (DOI: 10.2210/pdb4wer/pdb). The rationale for this 
adjustment was that the C-terminal end of LBL-2 in SK2 (524-RFDDGL-529) has sequence 
features that are more closely related to prokaryotic diacylglycerol kinases than to SK1 (Figure S1 
in Adams et al39). 
Our activity data for the normethyl analogue (18) of PF-543 suggested that the central ring 
methyl group in PF-543 is not a key SK2-discriminating feature and determinant of the high SK1-
inhibitory selectivity exhibited by PF-543. Nevertheless, we did find that energy minimisation of 
our ligand probe set docked into the SK2 model, as illustrated for 60 in Figure 5A, tended to result 
in contraction of the J-channel notch that hosts the PF-543 methyl. This notch is formed at the 
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interface between helices-α8 and -α9 of the two flap-like LBL-1 and LBL-3 loops respectively (cf. 
Figure 1). As such, size and surface contouring of the notch may be sensitive to subtle changes in 
the seating of the two helices as well as to accessible conformational volumes of local residues. 
Indeed, inspection of an overlay of all protein chains from the currently available crystal structures 
revealed significant differences in the notch surface even across different SK1 structures, thus 
suggesting a degree of plasticity in this region of the J-channel (Figure 5B and 5C). A particularly 
important residue in this regard is Leu299 in SK1, which is located on helix-α9 and conserved in 
SK2 as Leu544 (marked in Figure 5). This residue exhibits some conformational variance across 
SK1 crystal structures and would expand the notch region in the SK2 model illustrated in Figure 
5 to accommodate the PF-543 methyl group with only modest movement.
Figure 5. Comparison of modelled binding mode for SK2-selective inhibitor 60 with SK1 co-
crystal structures of PF-543 (1) and SKi (10). Panel (A): 60 (blue stick) docked into SK2 model 
(red mesh), highlighting key contact residues (cyan stick) and expanded SK2 J-channel toe surface. 
Panel (B): PF-543 (1; orange stick) is shown from its co-crystal structure (4V24) with SK1 (green 
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mesh) and the SK2 model surface (red mesh) overlaid from (A); SK1 contact residues are shown 
(light orange stick) and the constrained SK1 J-channel toe surface is evident. Panel (C): As (B), 
but showing co-crystal structure (3VZD) of SKi (10, magenta stick) with SK1 (blue mesh and pink 
stick key contact residues) superimposed onto the SK2 model (red mesh) from panel (A); the heel 
region adjacent to SK1 Leu302 is consistently less compressed in SK1 structures (relative to the 
SK2 model), whilst the notch surface exhibits some plasticity. Panel (D): overlay of (A)–(C) 
minus the J-channel surface; the chlorine atom of 60 is accommodated in SK2 between Cys533 
and Leu506, with rotation of the latter possible whilst the cognate SK1 residue (Leu261) is 
constrained by the packing of adjacent residues.
Although the notch region exhibits significant plasticity, inspection of the SK1 J-channel 
across different crystal structures revealed that the protein surface is quite tightly defined 
(irrespective of ligand occupancy) both around the J-channel heel that contacts the PF-543 sulfonyl 
group and around the toe that interfaces with the end of the PF-543 terminal phenyl subunit. Our 
data indicate that sulfonyl replacement by methylene in compounds 23 and 49 enhances SK1-
inhibitory potency compared to the sulfonylmethylene-linked parent (18), which suggests that the 
sulfonylmethylene linker is already a little oversized for an optimal fit of the tail of the ligand to 
the SK1 J-channel. Thus, only a modest additional contraction in the SK2 J-channel at this point 
could generate a strongly unfavourable compressive effect for compounds such as PF-543 and its 
normethyl analogue (18) to account for their SK1 selectivity. The SK2 model supported the 
proposal that the SK2 J-channel may be contracted in the heel region, in particular due to inwards 
movement of Leu547 (corresponding to Leu302 in SK1), Figure 6A. However, the model also 
suggested that the basis for such movement may be a consequence, at least in part, of differences 
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in the LBL-2/LBL-3 interfaces of the isoforms and not merely due to local residue differences 
immediately surrounding the leucine, as we had first conceived (Figure 2). In particular, Leu547 
is located on helix-α9 in LBL-3, and the C-terminal end of this helix engages the hairpin-like tip 
of LBL-2 (Figure 6a). The model suggested that residue differences in LBL-2 might promote an 
inward movement at the C-terminus of helix-α9, thereby exerting leverage on the J-channel heel 
through Leu547. As the key heel compression contact is against the Cβ atom of Leu547, rather 
than the end of the side chain, the leverage cannot be alleviated by side chain rotation. However, 
compounds with reduced steric demand in the heel (23 and 49) can be accommodated in both SK1 
and SK2 (illustrated for 49 in Figure 6B and 6C).
Figure 6. The J-channel heel is a key determinant of isoform discrimination by SK inhibitors. 
Panel (A): LBL-2 and LBL-3 are shown from the co-crystal structure (4V24) of PF-543 (orange 
stick) with SK1 (green ribbon); the corresponding elements from our SK2 homology model (red 
ribbon) are overlaid, illustrating inward movement in LBL-3 leading to heel compression in SK2 
by Leu547. Panel (B): Potent unselective inhibitor 49 (blue stick) is shown modelled into the SK2 
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J-channel (red mesh); the J-channel heel surface is driven significantly inwards relative to SK1 so 
that the presence of a sulfonyl group in the ligand (49  19, 56-fold activity loss) is poorly 
tolerated by SK2. Panel (C): Inhibitor 49 (magenta stick) is again shown, here modelled into the 
SK1 J-channel (green mesh); the SK1 J-channel heel surface exhibits less compression and 
accommodates a sterically more demanding sulfonyl containing linker more readily (49  19, no 
activity loss; 23  18, 5-fold activity loss). Panel (D): overlay of (B) and (C) minus the J-channel 
surface. 
The model also suggested that the strong SK2 selectivity of the para-halo derivatives of 
49/58 is indeed likely due to J-channel toe surface expansion, but that this may not be solely due 
to the single amino acid substitution of Phe288 in SK1 by Cys533 in SK2 (Figure 2). Indeed, in 
the absence of halogen substituents on the ligand, the energy minimised SK2 model complexes 
showed little apparent expansion in the toe surface compared to SK1, as illustrated for 49 docked 
to SK2 and SK1 (Figure 6B and 6C respectively). The key to accommodation of the para-halo 
atom appears to be perturbation in the conformation of an adjacent leucine (Leu506 in SK2, 
conserved in SK1 as Leu261) that packs against the cysteine. The combination of Cys533 and 
Leu506 generates the toe surface in SK2 (Figure 5), with movement of the latter predicted to allow 
expansion to accommodate the chlorine of 55/60. The leucine additionally packs against two other 
non-conserved residues––Val304 (Ile174 in SK1) and Ile508 (Leu263 in SK1)––and our model 
suggests that loosened packing with these residues and the cysteine may confer greater plasticity 
in the toe of the SK2 J-channel than in SK1. Thus, ligand binding in SK2 may involve an element 
of induced fit in the J-channel toe, potentially with an associated energy cost that is more or less 
offset depending on the effectiveness of surface contact between the ligand and the expanded toe. 
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In contrast, the toe of the SK1 J-channel is likely to be more rigid and introduction of para-
substitution in the ligand is predicted to generate an unfavourable compression between the J-
channel toe and helix-α9, as illustrated in Figure 7 for chloride 60. Despite the enhanced plasticity 
and capacity indicated for the SK2 J-channel toe, our results nevertheless indicate significant 
limitations on the size of the para-substituent that can be accommodated in SK2. Thus, the axis of 
the para-substituent is predicted to orientate directly at the Cβ atom of Ile508 presented from the 
SK2 CTD β-sandwich core, Figure 5A. In the case of chloride 60, a distance of ca. 4.3 Å is 
predicted between Ile508 Cβ and the chlorine atom, and this spatial constraint likely contributes 
to the sharp drop in inhibitory potency against SK2 seen with the introduction of a para-cyano 
group in 57. 
Figure 7. The J-channel toe is a second key determinant for isoform discrimination by SK 
inhibitors. A comparison of modelled binding modes for the SK2-selective inhibitor (60) is shown 
here, with the SK2-docked inhibitor (cyan stick) superimposed onto the SK1-docked inhibitor 
(magenta stick). With reduced plasticity in the SK1 J-channel toe (pink mesh), the sulfur atom of 
60 is predicted to be tightly wedged against the backbone of helix-α9 (pink ribbon). This generates 
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an unfavourable compression axis (black arrow, corresponding to ‘Axis-2’ of Figure 3) that 
preferentially penalizes binding to SK1. In SK2 the greater plasticity of the J-channel toe (cyan 
mesh) is predicted to allow accommodation of 60 with less compression.
During the course of our work, Childress et al36 described a series of pyrrolidine 
carboximidamide SK inhibitors with a spectrum of SK1- and SK2-inhibitory selectivity. The 
highest SK2-selectivity was seen with compound 9, which is notable for its extended tail structure. 
With the guanidinium head group engaging key acidic residues in the mouth of the J-channel, the 
aminothiazole subunit in 9 would be expected to overlay the middle arene subunit of our ligands, 
whilst the oxadiazole ring of 9 would lie in plane and partially map onto the p-xylylene subunit 
(Figure 8B/C). However, an intriguing feature with such a binding mode is that the rod like 
biphenyl tail of 9 could only be accommodated if there is a significant expansion in the toe of the 
J-channel, and this on the other side of Cys533 to that occupied by the chlorine in 55/60. There are 
two key residue substitutions that may make this possible for SK2 but not readily achievable for 
SK1: one is the replacement of SK1 Phe288 by Cys533 in SK2; the second is the exchange of SK1 
Met312 for Phe557 in SK2. In the absence of compound 9 the latter residue, which is surface 
exposed on LBL-3, is predicted to fold inwards towards the adjacent cysteine (in partial surrogacy 
for the Phe288 residue of SK1). Rotation of these two side chains alone (Cys533/Phe557) was 
sufficient to open an extended pocket in our model and accommodate the terminal phenyl group 
of 9 with a reasonably relaxed biphenyl torsion (37°) and favourable packing interactions against 
Cys533, Phe557 and other aromatic residues (Tyr, His). This postulated binding mode for 9, in 
effect, amounts to tunnelling between LBL-2 and LBL-3 in SK2. In SK1 the more rigid J-channel 
toe is stoppered by Phe288, for which a rotation analogous to that required of Cys533 in SK2 is 
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sterically precluded. The suggested binding mode for ligand 9 would also avoid encroachment on 
the Leu547 heel compression point in SK2 that we propose biases inhibitor selectivity towards 
SK1. Binding of compound 9 to SK1 would require much more extensive perturbation to the 
protein structure and packing of the LBL-3 return leg. 
Figure 8. Plasticity in the J-channel toe of SK2 may be exploited to develop SK2-selective 
inhibitors. Panel (A): Compound 60 (blue stick) docked into the SK2 model (red mesh), 
highlighting key contact residues (cyan stick) and two predicted trajectories for possible toe 
expansion (arrows). Small groups may be accommodated between Cys533 and Leu506 
(Trajectory-1, hollow arrow). This is the predicted expansion for binding of 55/60, where the fit 
of the Cl atom is likely made possible largely by rotation in Leu506. Larger groups may be 
accommodated between Cys533 and Phe557 (Trajectory-2, filled arrow) upon rotation of these 
side chains. Panel (B): VT-20dd (9, green stick) docked into the SK2 model (grey mesh), 
highlighting key contact residues (orange stick). Here the ligand is predicted to exploit the second 
toe expansion trajectory. Panel (C): Overlay of (A) and (B) showing the SK2 J-channel surface 
Page 28 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
for docked 60 (red mesh) and illustrating the two key residue rotations in Cys533 and Phe557 
required for Trajectory-2 expansion (cyan stick  orange stick positions). Panel (D): ABC294640 
(4, orange stick) docked into SK2 (grey mesh). In this model, the Trajectory-1 expansion is made 
possible chiefly by rotation of Cys533 rather than Leu506, but the space generated by the 
expansion is underused by the Cl atom.
Although our analysis suggests that outward rotation of Phe557 might allow tunnelling of 
substantially extended ligand tail groups in SK2 (Figure 8C), the preferred orientation of the 
Phe557 side chain (in the absence of such ligand extensions) is predicted to lie inwards towards 
Cys533 to maximise surface contact with adjacent hydrophobic residues.  In this tightly packed 
inward orientation, the end of the Phe557 side chain is predicted to come into close contact with 
the meta-position of the terminal phenyl ring of our PF-543-derived ligands series. This might 
contribute to the poor tolerance by SK2 of meta-halogenation, as seen with 51 and 54 (vide supra). 
In SK1 the cognate residue (Met312, Figure 2) is more flexible and exhibits less reach compared 
to Phe557 in SK2, which is consistent with the greater tolerance towards meta-halogenation in 51 
and 54. A suitable tail extension to enable tunnelling in SK2 (‘Trajectory-2’ in Figure 8) may 
require a large group to provoke the necessary rotation in Phe557 and compensate for the loss of 
packing interactions between this residue and adjacent side chains. Whilst potentially interesting 
for future investigation, our objective here was to achieve selectivity control with conservative 
changes in the parent ligand structure, thereby keeping molecular weight within druglike bounds.
We also docked ABC294640 (4) into our SK2 model for comparison (Figure 8D). In this 
case we found that the pyridyl group closely overlays the p-xylylene subunit of our ligands whilst 
the adamantyl group sits well in the J-channel bend––partly overlaying the middle arene of our 
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compounds but also the tail linker (and again without encroaching severely on the Leu547 heel 
compression point). The plane of the terminal chlorophenyl group was slightly rotated relative to 
55/60, but the chlorine atom occupied a similar position to that proposed for the chlorine in our 
SK2-selective compound, 55.
CONCLUSIONS
Growing interest in the therapeutic potential of targets within the sphingolipid signalling pathway 
is fueling efforts to develop isoform-selective SK inhibitors across a range of chemotypes.51-53 PF-
543 has attracted significant attention as a nanomolar-potent SK1-selective inhibitor. However, a 
structural basis for the compound’s SK1-over-SK2 selectivity has not been described until now, 
despite the recent disclosure of activity data for additional analogues.35 Moreover, a lack of 
discriminating nanomolar-potent SK2-selective inhibitors as signalling pathway probes has 
hindered thorough exploration of the pharmacological potential of SK2 as a distinct target to date. 
From a clinical perspective, the most advanced compound remains the micromolar-potent, SK2-
selective inhibitor, ABC294640 (4). However, the biological activity of this compound is 
complicated because it is a modulator of dihydroceramide desaturase and induces the proteasomal 
degradation of SK1.31-33
In order to develop a qualitative structural rationale for the design of isoform-selective 
inhibitors, we mapped SK2 sequence differences onto our recently determined38 SK1/PF-543 co-
crystal structure. That analysis (Figure 2) suggested a focus on the heel and toe of the J-channel, 
which we then probed with a concise set of PF-543 analogues modified in the tail linker and 
terminal phenyl ring (Chart 2). Our studies indicate that the phenyl group of PF-543, which is 
tightly fitted to the toe of the ligand-binding J-channel, constrains placement of the sulfonyl 
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oxygens of the ligand into a region of surface encroachment in the J-channel heel of SK2. Deleting 
the sulfonyl oxygens by installation of replacement linkers for the PF-543 sulfonylmethylene 
group endows the ligand with dual SK1/SK2-inhibitory activity (23, 49, 58). In contrast to the 
heel, our work suggests that the surface of the J-channel toe in SK2 may be expanded and exhibit 
greater plasticity compared to SK1. We have shown that this difference may be exploited with a 
suitably positioned halogenated terminal arene in the ligand to undermine inhibition of SK1. 
Coupled with replacement of the PF-543 sulfonylmethylene linker, this strategy allows full 
reversal in the SK isoform selectivity profile to be engineered, with up to 100-fold selectivity for 
SK2 over SK1 achieved in our series with p-chlorophenyl terminal ligand subunits. Comparative 
analysis of another recently disclosed SK2-selective inhibitor (9)36 suggests an additional tail 
trajectory where ligand extensions may be accommodated through plasticity in SK2 that does not 
exist in SK1. Taken together, we suggest that these studies now provide a blueprint for rational 
design of isoform-selective SK inhibitors and the development of suitable tool compounds for 
further exploring the pharmacological potential of SK2 as a therapeutic target. 
EXPERIMENTAL SECTION
SK1 and SK2 assays. Sphingosine kinase assays employed purified SK1 or purified SK2 
(40-180 ng/ml) and were performed using the Km concentrations of Sph (3 and 10 µM, 
respectively) and 250 µM [γ-32P]ATP (0.75 kBq/nmol) for 30 min at 30 °C in a buffer containing 
20 mM Tris (pH 7.4), 1 mM EDTA, 1 mM Na3VO4, 40 mM β-glycerophosphate, 1 mM NaF, 
0.007% (v/v) β-mercaptoethanol, 20% (v/v) glycerol, 10 μg/mL aprotinin, 10 μg/mL soybean 
trypsin inhibitor, 1 mM PMSF, 0.5 mM 4-deoxypyridoxine (and 400 mM KCl in the case of SK2 
assays). Sph was presented in Triton X-100 (final concentration, 0.063% w/v) for SK1 whereas 
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fatty acid free bovine serum albumin (final concentration, 0.2 mg/mL) was used in SK2 assays. 
Inhibitors were dissolved and diluted in DMSO (5% v/v final in assay). 32P-sphingosine 1-
phosphate was extracted with 500 μL of 1-butanol, followed by a phase-split using 1 mL of 2 M 
KCl and two washes of the lower (aqueous) phase, using 2 M KCl, to remove unreacted [γ-32P]ATP 
before harvesting the upper (organic) phase and quantification by Cerenkov counting.
Synthetic chemistry general methods. Solvents and reagents were procured from 
commercial suppliers (Acros, Geel, Belgium; Alfa Aesar, Heysham, United Kingdom; Apollo 
Scientific, Stockport, United Kingdom; Fisher Scientific, Loughborough, United Kingdom; 
Fluorochem, Hadfield, United Kingdom; Sigma-Aldrich, Gillingham, United Kingdom) and used 
as supplied without further purification unless otherwise stated. “Light petroleum” refers to the 
fraction boiling between 40 and 60 °C. Analytical thin layer chromatography was carried out using 
aluminum backed plates coated with Merck Kieselgel 60 GF254 (No. 05554). Developed plates 
were visualized under ultraviolet light (254 nm and 366 nm) and/or by alkaline potassium 
permanganate dip. Preparative chromatography was performed (a) in conventional glass columns 
under flash column chromatography conditions (silica gel of 40–63 µm particle size from Fisher 
Scientific); or (b) using SP4 Biotage MPLC apparatus with silica gel of 40–63 µm particle size 
(Fisher Scientific) in 10 g or 50 g cartridges depending on the scale of material to be processed; or 
(c) using Strata® SI-1 cartridges (Phenomenex). Fully characterized compounds were 
chromatographically homogeneous. 1H NMR spectra were recorded at 400 MHz on JEOL Lambda 
Delta 400, Bruker AMX-400 and Bruker AVIII-400 spectrometers; 13C NMR spectra were 
recorded at 101 MHz on the same instruments. Chemical shifts are recorded in parts per million 
(δ in ppm) and are referenced against solvent signals (δC 77.16 for chloroform and δC 39.52 for 
methyl sulfoxide) for 13C spectra and solvent residual resonances (δH 7.26 for chloroform and δH 
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2.50 methyl sulfoxide) for 1H spectra.54 1H and 13C chemical shift values are accurate to ±0.01 
ppm and ±0.1 ppm respectively. J values are given in Hz. Multiplicity designations used are as 
follows: s, d, t, q, sept, and m for singlet, doublet, triplet, quartet, septet, and multiplet 
(respectively); br denotes an exchange-broadened signal. 13C signal assignments, taken from 
distortionless enhancement by polarization transfer (DEPT) experiments, are listed in parenthesis. 
High-resolution mass spectroscopy (HRMS) was carried out under electrospray ionisation (ESI), 
in a Fourier transform analyser by Exactive® ThermoFisher Scientific instrument. All compounds 
subjected to enzyme assay evaluation were ≥95% pure as determined by HPLC analysis. HPLC 
Method (A): YMC hydrosphere C18 5 µm / 12 nm (150 × 4.5 mm) column under isocratic elution 
[0.1% CF3CO2H in 35/65 water/MeCN] at 0.7 mL/min and 40 °C with detection at λ 230 nm. 
HPLC Method (B): Poroshell 120 C18 2.7 µm (75 x 4.6 mm) column under gradient elution from 
95% water (5 mM NH4OAc) and 5% MeCN (5 mM NH4OAc) to 100% MeCN (5 mM NH4OAc) 
at 1 mL/min and 40 °C with detection at λ 214 nm.
1-Methoxy-3-((phenylsulfonyl)methyl)benzene (12). A mixture of 11 (7.58 g, 37.7 
mmol), sodium benzene sulfinate (NaSO2Ph, 6.75 g, 41.1 mmol) and Aliquat® 336 (0.28 g, 0.70 
mmol) was stirred at 85 °C for 18 h. The reaction mixture was diluted with hot EtOAc (120 mL), 
stirred at ambient temperature for 1 h and the resulting slurry filtered through Celite® to afford a 
filtrate that was concentrated in vacuo. The residue was subjected to flash column chromatography 
(light petroleum/EtOAc gradient 4:1 to 1:1) to afford 12 (4.61 g, 47%) as a white powder. 1H NMR 
(400 MHz, CDCl3) δ 3.71 (s, 3H), 4.28 (s, 2H), 6.61 (t, J = 2.2 Hz, 1H), 6.64 (ddd, J = 7.4, 1.6, 
1.0 Hz, 1H), 6.85 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 7.44–7.48 (m, 2H), 7.58–
7.63 (m, 1H), 7.64–7.67 (m, 2H). 
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3-((Phenylsulfonyl)methyl)phenol (14). To a solution of 12 (1.31 g, 5.00 mmol) in 
anhydrous CH2Cl2 (30 mL) at –78 °C under N2 was added dropwise BBr3 (1 M in CH2Cl2; 5.50 
mL, 5.50 mmol). The mixture was allowed to come to ambient temperature over 2 h and then 
cooled to 0°C and quenched with saturated NaHCO3 (40 mL). The separated aq. phase was back 
extracted with CH2Cl2 (2×30 mL). The combined organics were washed with brine (2×15 mL), 
dried (Na2SO4) and filtered. The filtrate was evaporated and the resulting residue subjected to flash 
column chromatography (CH2Cl2/MeOH gradient 99.5:0.5 to 99:1) to afford 14 (958 mg, 77%) as 
a white powder. 1H NMR (400 MHz, CDCl3) δ 4.26 (s, 2H), 4.88 (s, 1H), 6.58 (ddd, J = 7.6, 1.6, 
0.9 Hz, 1H), 6.66 (1 H, app. t, J 2.0), 6.79 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 7.10 (t, J = 7.9 Hz, 1H), 
7.44–7.49 (m, 2H), 7.59–7.63 (m, 1H), 7.65–7.68 (m, 2H). 
3-Hydroxyphenyl benzenesulfonate (15). A mixture of resorcinol (500 mg, 4.54 mmol), 
K2CO3 (1.88 g, 13.6 mmol) and phenylsulfonyl chloride (637 μL, 4.99 mmol) in MeCN (6 mL) 
was stirred at ambient temperature for 16 h. The mixture was partitioned between Et2O and water, 
and the separated organic phase then washed with saturated K2CO3 solution and extracted with 1 
M NaOH (aq). The aqueous extract was acidified with 3 M HCl (aq) and back extracted with Et2O. 
The organic phase was dried (MgSO4) and evaporated to afford 15 (244 mg, 21%) as a beige solid. 
1H NMR (400 MHz, DMSO-d6) δ 6.37–6.47 (m, 2H), 6.69 (dd, J = 8.1, 1.5 Hz, 1H), 7.11–7.15 
(m, 1H), 7.65–7.69 (m, 2H), 7.81 (t, J = 7.5 Hz, 1H), 7.86 (d, J = 7.6 Hz, 2H), 9.87 (br s, 1H). 13C 
NMR (101 MHz, DMSO-d6) δ 106.2, 109.0, 112.1, 114.5, 128.1, 128.1, 129.7, 134.9, 149.8, 158.5. 
4-((3-((Phenylsulfonyl)methyl)phenoxy)methyl)benzaldehyde (16). A stirred mixture 
of 14 (283 mg, 1.14 mmol), 4-(bromomethyl)benzaldehyde (239 mg, 1.20 mmol) and K2CO3 (440 
mg, 3.19 mmol) in MeCN (8.0 mL) was heated at 60 °C for 3 h. The mixture was filtered through 
Celite® to afford a filtrate that was concentrated in vacuo. The residue was partitioned between 
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EtOAc (50 mL) and water (20 mL). The organic phase was washed with brine (15 mL), dried 
(MgSO4) concentrated and processed by flash column chromatography (CH2Cl2 to 0.5% 
MeOH/CH2Cl2 gradient elution) to afford 16 (338 mg, 81%) as a white powder. 1H NMR (400 
MHz, CDCl3) δ 4.28 (s, 2H),5.07 (s, 2H), 6.65 (ddd, J = 7.5, 1.6, 0.9 Hz, 1H), 6.78 (dd, J = 2.5, 
1.6 Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 7.16 (dd, J = 8.3, 7.6 Hz, 1H), 7.43–7.48 (m, 
2H), 7.55–7.58 (m, 2H), 7.58–7.63 (m, 1H), 7.63–7.67 (m, 2H), 7.89–7.92 (m, 2H), 10.03 (s, 1H). 
13C NMR (101 MHz, CDCl3) δ 62.8 (CH2), 69.2 (CH2), 115.6 (CH), 117.0 (CH), 123.9 (CH), 
127.5 (2×CH), 128.6 (2×CH), 128.9 (2×CH), 129.6 (C), 129.7 (CH), 133.1 (CH), 130.0 (2×CH), 
136.1 (C), 138.0 (C), 143.6 (C), 158.4 (C), 191.8 (CO). 
3-((4-Formylbenzyl)oxy)phenyl benzenesulfonate (17). Following the procedure for 16, 
phenol 15 (150 mg, 0.568 mmol) afforded 17 (196 mg, 88%) as a colourless solid. 1H NMR (400 
MHz, DMSO-d6) δ 5.16 (s, 2H), 6.62 (ddd, J = 8.1, 2.2, 0.8 Hz, 1H), 6.69–6.70 (m, 1H), 6.99 (ddd, 
J = 8.4, 2.5, 0.8 Hz, 1H), 7.27–7.31 (m, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.66 (dd, J = 8.2, 7.5 Hz, 
2H), 7.77–7.84 (m, 1H), 7.86 (dd, J = 8.2, 1.3 Hz, 2H), 7.93 (d, J = 8.1 Hz, 2H), 10.02 (s, 1H). 13C 
NMR (101 MHz, DMSO-d6) δ 68.9, 108.9, 114.1, 114.3, 127.8, 128.2, 129.7, 129.7, 130.5, 134.2, 
135.0, 135.7, 143.3, 149.8, 158.8, 192.8.
(R)-(1-(4-((3-((Phenylsulfonyl)methyl)phenoxy)methyl)benzyl)pyrrolidin-2-
yl)methanol (18). To a solution of 16 (96 mg, 0.262 mmol) and (R)-(–)-2-pyrrolidinemethanol (28 
μL, 0.287 mmol) in 1,2-dichloroethane (2 mL) was added NaBH(OAc)3 (83 mg, 0.393 mmol). 
The mixture was stirred at ambient temperature for 16 h. A further portion of NaBH(OAc)3 (28 
mg, 0.13 mmol) was added and stirring continued for 18 h until complete consumption of 16 was 
observed by TLC analysis (CH2Cl2/MeOH 9:1). The mixture was diluted with CH2Cl2 (30 mL) 
and washed with saturated NaHCO3 solution (10 mL). The organic phase was dried (MgSO4), 
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evaporated and the resulting residue subjected to flash column chromatography (gradient elution, 
1% to 5% MeOH in CH2Cl2) to afford 18 (84 mg, 71%) as a white powder. 1H NMR (400 MHz, 
CDCl3) δ 1.65–1.75 (m, 2H), 1.80–1.88 (m, 1H), 1.88–1.99 (m, 1H), 2.30 (q, J = 8.4 Hz, 1H), 
2.40–3.00 (br s, 1H), 2.72–2.78 (m, 1H), 2.96–3.01 (m, 1H), 3.38 (d, J = 13.0 Hz, 1H), 3.44 (dd, 
J = 10.8, 2.2 Hz, 1H), 3.66 (dd, J = 10.8, 3.5 Hz, 1H), 3.98 (d, J = 13.0 Hz, 1H), 4.28 (s, 2H), 4.94 
(s, 2H), 6.64 (dt, J = 7.6, 1.2 Hz, 1H), 6.73 (dd, J = 2.5, 1.7 Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 
Hz, 1H), 7.15 (dd, J = 8.3, 7.6 Hz, 1H), 7.29–7.37 (m, 4H), 7.43–7.48 (m, 2H), 7.58–7.63 (m, 1H), 
7.63–7.66 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 23.5 (CH2), 27.8 (CH2), 54.5 (CH2), 58.3 (CH2), 
61.8 (CH2), 62.9 (CH2), 64.4 (CH), 69.9 (CH2), 115.7 (CH), 117.0 (CH), 123.4 (CH), 127.6 
(2×CH), 128.7 (2×CH), 128.9 (2×CH), 128.9 (2×CH), 129.5 (C), 129.6 (CH), 133.7 (CH), 135.5 
(C), 138.0 (C), 139.3 (C), 158.8 (C). ESI-HRMS [M + H]+ calcd for C26H30NO4S+, 452.1890; 
found, 452.1904. HPLC: Method (A) tR 3.89 min (99.5%).
(R)-3-((4-((2-(Hydroxymethyl)pyrrolidin-1-yl)methyl)benzyl)oxy)phenyl 
benzenesulfonate (19). Following the procedure for 18, aldehyde 17 (100 mg, 0.271 mmol) 
afforded 19 (40 mg, 33%) as a colourless oil. 1H NMR (400 MHz, DMSO-d6) δ 1.52–1.65 (m, 
3H), 1.79–1.88 (m, 1H), 2.10–2.16 (m, 1H), 2.52–2.59 (m, 1H), 2.73–2.78 (m, 1H), 3.26–3.31 (br 
m, 1H), 3.33 (d, J = 13.3 Hz, 1H), 3.45 (br. dd, J = 10.3 and 3.9 Hz, 1H), 4.04 (d, J = 13.3 Hz, 
1H), 4.38 (br s, 1H), 4.98 (s, 2H), 6.59 (ddd, J = 8.2, 2.2 and 0.7 Hz, 1H), 6.66 (t, J = 2.3 Hz, 1H), 
6.96 (ddd, J = 8.4, 2.4 and 0.7 Hz, 1H), 7.27 (t, J = 8.3 Hz, 1H), 7.31 (app. s, 4H), 7.64–7.69 (m, 
2H), 7.80–7.84 (m, 1H), 7.84–7.87 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 22.5, 28.0, 54.0, 
58.4, 64.2, 64.8, 69.5, 108.8, 114.0, 127.6, 128.2, 128.6, 129.7, 130.4, 134.3, 134.6, 135.0, 139.9, 
148.8, 149.8, 159.2. ESI-HRMS [M + H]+ calcd for C25H28NO5S+, 454.1683; found, 454.1681. 
HPLC: Method (B) tR 6.64 min (96.7%).
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3-(Phenylethynyl)phenol (20). A flask was charged under Ar with 3-iodophenol (1.51 g, 
6.86 mmol), copper(I) iodide (140 mg, 734 µmol), tetrakis(triphenylphosphine)palladium(0) (382 
mg, 332 µmol), anhydrous THF (30 mL), triethylamine (24 mL) and phenylacetylene (2.80 g, 27.4 
mmol). The mixture was stirred at ambient temperature for 48 h, concentrated in vacuo and the 
resulting residue partitioned between CHCl3 (100 mL) and 1 M HCl (aq) (200 mL). The organic 
phase was dried (MgSO4) and evaporated. The residual oil was processed by flash column 
chromatography (1:2:8 Et2O/CH2Cl2/light petroleum) followed by crystallisation (CH2Cl2/light 
petroleum) to afford 20 (759 mg, 57%) as off-white plates. 1H NMR (400 MHz, CDCl3) δ 4.77 
(br. s, 1H), 6.83 (ddd, J = 8.1, 2.6 and 1.0 Hz, 1H), 7.01 (dd, J = 2.4 and 1.4 Hz, 1H), 7.13 (dt, J = 
7.6 and 1.2 Hz, 1H), 7.23 (t, J = 7.9 Hz, 1H), 7.31–7.38 (m, 3H), 7.50–7.55 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 89.1 (C), 89.6 (C), 115.9 (CH), 118.4 (CH), 123.3 (C), 124.6 (CH), 124.7 
(C), 128.5 (3×CH), 129.8 (CH), 131.8 (2×CH), 155.4 (C).
3-Phenethylphenol (21). A solution of 20 (400 mg, 2.06 mmol) in EtOH (40 mL) was 
hydrogenated using an H-Cube™ (ThalesNano) fitted with a 10% Pd/C cartridge under full H2 
mode at 30 °C with a flow rate of 0.7 mL/minute. The hydrogenated product solution was 
evaporated to 21 (390 mg, 95%) as a colourless oil that solidified to a crystalline solid on standing. 
1H NMR (400 MHz, CDCl3) δ 2.86–2.95 (m, 4H), 4.68 (br. s, 1H), 6.67–6.69 (m, 2H), 6.78 (app. 
d, J = 7.5 Hz, 1H), 7.14–7.23 (m, 4H), 7.27–7.32 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 37.75 
(CH2), 37.80 (CH2), 113.0 (CH), 115.6 (CH), 121.2 (CH), 126.1 (CH), 128.5 (2×CH), 128.6 
(2×CH), 129.7 (CH), 141.8 (C), 143.9 (C), 155.5 (C).
4-((3-Phenethylphenoxy)methyl)benzaldehyde (22). A mixture of 4-
(bromomethyl)benzaldehyde (301 mg, 1.51 mmol), 21 (337 mg, 1.70 mmol) and K2CO3 (707 mg, 
5.12 mmol) in MeCN (10 mL) was stirred at ambient temperature for 16 h. The mixture was diluted 
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with CH2Cl2 (25 mL), filtered through Celite® and the filtrate evaporated to dryness. The residual 
oil was processed chromatographically (20 g Strata® SI-1 cartridge; 1 : 39 : 60 Et2O/CH2Cl2/light 
petroleum) to afford 22 (417 mg, 87%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 2.86–
2.96 (m, 4H), 5.12 (s, 2H), 6.79–6.84 (m, 3H), 7.16–7.23 (m, 4H), 7.26–7.31 (m, 2H), 7.59–7.62 
(AAʹBBʹ m, 2H), 7.89–7.92 (AAʹBBʹ m, 2H), 10.03 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 37.8 
(CH2), 38.0 (CH2), 69.2 (CH2), 112.2 (CH), 115.3 (CH), 121.7 (CH), 126.1 (CH), 127.6 (2×CH), 
128.45 (2×CH), 128.55 (2×CH), 129.5 (CH), 130.1 (2×CH), 136.0 (C), 141.7 (C), 143.7 (C), 144.3 
(C), 158.5 (C), 192.0 (CH).
(R)-(1-(4-((3-Phenethylphenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol (23). 
Following the procedure for 18, aldehyde 22 (417 mg, 1.32 mmol) afforded 23 (432 mg, 82%) as 
a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.66–1.76 (m, 2H), 1.81–2.00 (m, 2H), 2.30 (td, J 
= 9.3 and 7.5 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.73–2.78 (m, 1H), 2.88–2.96 (m, 4H), 2.97–3.02 (m, 
1H), 3.39 (d, J = 13.1 Hz, 1H), 3.45 (dd, J = 10.8 and 1.9 Hz, 1H), 3.68 (dd, J = 10.8 and 3.5 Hz, 
1H), 3.99 (d, J = 13.1 Hz, 1H), 5.02 (s, 2H), 6.80–6.84 (m, 3H), 7.19–7.23 (m, 4H), 7.28–7.41 (m, 
6H). 13C NMR (101 MHz, CDCl3) δ 23.6 (CH2), 27.9 (CH2), 37.9 (CH2), 38.1 (CH2), 54.5 (CH2), 
58.3 (CH2), 61.9 (CH2), 64.4 (CH), 69.8 (CH2), 112.3 (CH), 115.3 (CH), 121.2 (CH), 126.0 (CH), 
127.7 (2×CH), 128.4 (2×CH), 128.5 (2×CH), 129.0 (2×CH), 129.4 (CH), 136.0 (C), 139.2 (C), 
141.8 (C), 143.5 (C), 159.0 (C). ESI-HRMS [M + H]+ calcd for C27H32NO2+, 402.2428; found, 
402.2434. HPLC: Method (A) tR 4.73 min (>99%).
3-(Benzyloxy)phenol (25). A heavy-walled sealable reaction flask was charged with 
resorcinol (2.20 g, 20.0 mmol), K2CO3 (2.80 g, 20.3 mmol), acetone (30 mL) and a magnetic stir 
bar. Benzyl bromide (1.72 g, 10.1 mmol) was added and the flask closed under Argon. The mixture 
was then heated at 65–70 °C. After 5 h the mixture was returned to ambient temperature and 
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filtered through Celite®, washing well with acetone. The filtrate was evaporated to afford a residue 
that was partitioned between CHCl3 (100 mL) and water (100 mL). The organic phase was 
separated and the aqueous layer extracted with CHCl3 (25 mL). The combined organic phase was 
dried (MgSO4) and evaporated to give a residue that was processed by flash column 
chromatography (25% Et2O/light petroleum). Fractions containing the target material were 
evaporated to afford 25 (1.11 g, 55%) as a colourless oil that solidified to a crystalline solid on 
standing. 1H NMR (400 MHz, CDCl3) δ 4.67 (br s, 1H), 5.04 (s, 2H), 6.44 (ddd, J = 8.0, 2.4 and 
0.9, 1H), 6.49 (t, J = 2.3, 1H), 6.58 (ddd, J = 8.3, 2.4 and 0.8, 1H), 7.14 (t, J = 8.1, 1H), 7.30–7.45 
(m, 5H). 13C NMR (101 MHz, CDCl3) δ 70.2 (CH2), 102.6 (CH), 107.6 (CH), 108.3 (CH), 127.6 
(2×CH), 128.1 (CH), 128.7 (2×CH), 130.3 (CH), 136.9 (C), 156.7 (C), 160.1 (C).
3-((2-Fluorobenzyl)oxy)phenol (26). Following the procedure for 25, 2-fluorobenzyl 
bromide (1.91 g, 10.1 mmol) afforded 26 (1.17 g, 53%) as a pale yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 4.86 (br s, 1H), 5.11 (s, 2H), 6.45 (ddd, J = 8.0, 2.4 and 0.8 Hz, 1H), 6.50 (t, J = 2.3 Hz, 
1H), 6.59 (ddd, J = 8.3, 2.4 and 0.8 Hz, 1H), 7.06–7.19 (m, 3H), 7.32 (tdd, J = 7.8, 5.6 and 2.1 Hz, 
1H), 7.47–7.53 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 63.9 (d, J = 4.5 Hz, CH2), 102.6 (CH), 
107.5 (CH), 108.5 (CH), 115.4 (d, J = 21.1 Hz, CH), 124.0 (d, J = 14.3 Hz, C), 124.4 (d, J = 3.6 
Hz, CH), 129.8 (d, J = 2.9 Hz, CH), 129.9 (d, J = 1.3 Hz, CH), 130.4 (CH), 156.6 (C), 159.9 (C), 
160.6 (d, J = 247.1 Hz, C). 19F NMR (282 MHz, CDCl3) δ –118.5.
3-((3-Fluorobenzyl)oxy)phenol (27). Following the procedure for 25, 3-fluorobenzyl 
bromide (1.91 g, 10.1 mmol) afforded 27 (1.27 g, 58%) as a pale yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 5.03 (s, 2H), 5.07 (br s, 1H), 6.44–6.49 (m, 2H), 6.57 (ddd, J = 8.3, 2.3 and 0.9 Hz, 1H), 
6.98–7.05 (m, 1H), 7.12–7.20 (m, 3H), 7.34 (td, J = 7.9 and 5.8 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ 69.3 (CH2), 102.6 (CH), 107.6 (CH), 108.5 (CH), 114.3 (d, J = 22.0 Hz, CH), 114.9 (d, 
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J = 21.1 Hz, CH), 122.9 (CH), 130.2 (d, J = 8.2 Hz, CH), 130.4 (CH), 139.5 (d, J = 7.3 Hz, C), 
159.8 (C), 161.4 (C), 163.1 (d, J = 246.1 Hz, C). 19F NMR (282 MHz, CDCl3) δ –112.6.
3-((4-Fluorobenzyl)oxy)phenol (28). Following the procedure for 25, 4-fluorobenzyl 
bromide (1.83 g, 9.67 mmol) afforded 28 (803 mg, 38%) as a colourless crystalline solid. 1H NMR 
(400 MHz, CDCl3) δ 4.98 (br s, 1H), 4.99 (s, 2H), 6.45 (ddd, J = 7.9, 2.3 and 0.8,1H), 6.48 (t, J = 
2.2, 1H), 6.56 (ddd, J = 8.3, 2.3 and 0.9,1H), 7.03–7.11 (m, 2H), 7.14 (t, J = 8.1, 1H), 7.36–7.43 
(m, 2H). 13C NMR (75 MHz, CDCl3) δ 69.5 (CH2), 102.7 (CH), 107.4 (CH), 108.4 (CH), 115.6 
(d, J = 21.4, CH), 129.5 (d, J = 8.2, CH), 130.3 (CH), 132.7 (d, J = 3.0, C), 156.9 (C), 160.0 (C), 
162.6 (d, J = 246, C). 19F NMR (282 MHz, CDCl3) δ –114.2.  
3-((2-Chlorobenzyl)oxy)phenol (29). Following the procedure for 25, 2-chlorobenzyl 
bromide (2.01 g, 9.79 mmol) afforded 29 (1.24 g, 54%) as a pale yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 4.72 (br s, 1H), 5.11 (s, 2H), 6.42 (dd, J = 8.0 and 2.3 Hz, 1H), 6.47 (t, J = 2.3 Hz, 1H), 
6.55 (dd, J = 8.2 and 2.3 Hz, 1H), 7.12 (t, J = 8.1, 1H), 7.19–7.29 (m, 2H), 7.32–7.39 (m, 1H), 
7.48–7.54 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 67.3 (CH2), 102.7 (CH), 107.5 (CH), 108.6 
(CH), 127.0 (CH), 129.0 (CH), 129.1 (CH), 129.4 (CH), 130.4 (CH), 132.7 (C), 134.5 (C), 156.7 
(C), 159.8 (C).
3-((3-Chlorobenzyl)oxy)phenol (30). Following the procedure for 25, 3-chlorobenzyl 
bromide (2.01 g, 9.77 mmol) afforded 30 (1.12 g, 49%) as a pale yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 4.90 (br s, 1H), 5.01 (s, 2H), 6.44–6.48 (m, 2H), 6.55 (ddd, J = 8.3, 2.2 and 1.1 Hz, 1H), 
7.11–7.18 (m, 1H), 7.28–7.40 (m, 3H), 7.32–7.39 (m, 1H), 7.42–7.44 (m, 1H). 13C NMR (75 MHz, 
CDCl3) δ 69.3 (CH2), 102.6 (CH), 107.5 (CH), 108.6 (CH), 125.5 (CH), 127.5 (CH), 128.2 (CH), 
129.9 (CH), 130.4 (CH), 134.5 (C), 138.9 (C), 156.6 (C), 159.8 (C).
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3-((4-Chlorobenzyl)oxy)phenol (31). Following the procedure for 25, 4-chlorobenzyl 
chloride (1.62 g, 10.1 mmol) afforded 31 (1.14 g, 48%) as a colourless crystalline solid. 1H NMR 
(400 MHz, CDCl3) δ 4.99 (s, 2H), 5.12 (br s, 1H), 6.43–6.48 (m, 2H), 6.56 (dd, J = 8.1 and 2.2, 
1H), 7.14 (t, J = 8.1, 1H), 7.30–7.40 (tight AAʹBBʹ m, 4H). 13C NMR (101 MHz, CDCl3) δ 69.5 
(CH2), 102.8 (CH), 107.6 (CH), 108.5 (CH), 128.9 (4×CH), 130.4 (CH), 133.9 (C), 135.5 (C), 
156.8 (C), 160.1 (C).
3-((4-Methoxybenzyl)oxy)phenol (32). Following the procedure for 25, 4-methoxybenzyl 
chloride (1.57 g, 10.0 mmol) afforded 32 (736 mg, 32%) as a white powder. 1H NMR (300 MHz, 
CDCl3) δ 3.82 (s, 3H), 4.67 (br s, 1H), 4.96 (s, 2H), 6.43 (1 H, ddd, J = 8.0, 2.4 and 0.8, 1H), 6.47 
(t, J = 2.3, 1H), 6.57 (ddd, J = 8.3, 2.4 and 0.8, 1H), 6.89–6.94 (AAʹBBʹ m, 2H), 7.13 (t, J = 8.2, 
1H), 7.33–7.37 (AAʹBBʹ m, 2H). 13C NMR (75 MHz, CDCl3) δ 55.5 (CH3), 70.0 (CH2), 102.6 
(CH), 107.5 (CH), 108.1 (CH), 114.2 (2×CH), 129.1 (C), 129.4 (2×CH), 130.3 (CH), 156.8 (C), 
159.4 (C), 160.3 (C).
4-((3-Hydroxyphenoxy)methyl)benzonitrile (33). Following the procedure for 25, 4-
cyanobenzyl bromide (1.96 g, 9.98 mmol) afforded 33 (1.05 g, 47%) as an off-white powder. 1H 
NMR (400 MHz, CDCl3) δ 4.90 (br s, 1H), 5.10 (s, 2H), 6.45–6.48 (m, 2H), 6.53 (ddd, J = 8.3, 
2.3 and 1.0, 1H), 7.12–7.17 (m, 1H), 7.52–7.55 (AAʹBBʹ m, 2H), 7.66–7.69 (AAʹBBʹ m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 69.1 (CH2), 102.7 (CH), 107.4 (CH), 108.8 (CH), 111.9 (C), 118.8 (C), 
127.7 (2×CH), 130.5 (CH), 132.6 (2×CH), 142.7 (C), 157.1 (C), 159.8 (C).
3-(Benzylthio)phenol (34). A mixture of 3-mercaptophenol (621 mg, 4.92 mmol), benzyl 
bromide (888 mg, 5.19 mmol) and K2CO3 (2.05 g, 14.8 mmol) in acetonitrile (10 mL) was stirred 
under Ar at ambient temperature. After 2 d the reaction mixture was diluted with CH2Cl2 (25 mL) 
and filtered through Celite®, washing well with CH2Cl2. The filtrate was evaporated and the 
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residue processed chromatographically (20 g Strata® SI-1 cartridge; 1:3:8 Et2O/CH2Cl2/light 
petroleum) to afford 34 (720 mg, 68%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 4.12 
(s, 2H), 4.90 (br. s, 1H), 6.64 (ddd, J = 8.1, 2.5 and 0.9 Hz, 1H), 6.78 (t, J = 2.1 Hz, 1H), 6.88 
(ddd, J = 7.8, 1.7 and 0.9 Hz, 1H), 7.13 (t, J = 7.9 Hz, 1H), 7.22–7.33 (m, 5H). 13C NMR (101 
MHz, CDCl3) δ 38.6 (CH2), 113.5 (CH), 116.1 (CH), 121.7 (CH), 127.4 (CH), 128.6 (2×CH), 
128.9 (2×CH), 130.0 (CH), 137.2 (C), 138.1 (C), 155.8 (C)
3-((4-Fluorobenzyl)thio)phenol (35). Following the procedure for 34, 3-mercaptophenol 
(500 µL, 4.91 mmol) was alkylated with 4-fluorobenzyl bromide (930 mg, 4.92 mmol) to afford 
35 (818 mg, 71%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 4.08 (s, 2H), 4.68 (br. s, 
1H), 6.65 (ddd, J 8.1, 2.5 and 0.9 Hz, 1H), 6.77 (ddd, J = 2.5, 1.7 and 0.3 Hz, 1H), 6.86 (ddd, J = 
7.8, 1.7 and 0.9 Hz, 1H), 6.94–7.00 (m, 2H), 7.13 (td, J = 7.9 and 0.3 Hz, 1H), 7.23–7.28 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 38.1 (CH2), 113.7 (CH), 115.5 (d, J = 21.5 Hz, 2×CH), 116.4 (CH), 
122.1 (CH), 130.1 (CH), 130.5 (d, J = 8.1 Hz, 2×CH), 133.1 (d, J = 3.2 Hz, C), 137.8 (C), 155.7 
(C), 162.1 (d, J = 245.7 Hz, C). 19F NMR (376 MHz, CDCl3) δ –115.3.
3-((4-Chlorobenzyl)thio)phenol (36). Following the procedure for 34, 3-mercaptophenol 
(500 µL, 4.91 mmol) was alkylated with 4-chlorobenzyl chloride (823 mg, 5.11 mmol) to afford 
36 (969 mg, 79%) as a colourless solid. 1H NMR (400 MHz, CDCl3) δ 4.06 (s, 2H), 4.72 (br. s, 
1H), 6.65 (ddd, J = 8.1, 2.5 and 0.9 Hz, 1H), 6.76 (app. t, J = 2.1 Hz, 1H), 6.86 (ddd, J = 7.8, 1.7 
and 0.9 Hz, 1H), 7.13 (app. t, J = 7.9 Hz, 1H), 7.21–7.27 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
38.2 (CH2), 113.8 (CH), 116.4 (CH), 122.2 (CH), 128.8 (2×CH), 130.1 (CH), 130.2 (2×CH), 133.1 
(C), 135.9 (C), 137.5 (C), 155.7 (C). 
4-((3-(Benzyloxy)phenoxy)methyl)benzaldehyde (37). To a solution of 25 (328 mg, 1.64 
mmol) in anhydrous DMF (6 mL) under argon was added NaH (60% w/w in mineral oil; 83.0 mg, 
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2.08 mmol). The mixture was sonicated for 2 min to aid dispersal of the hydride reagent and then 
stirred at ambient temperature for 15 min prior to addition of 4-(bromomethyl)benzaldehyde (365 
mg, 1.83 mmol). After a further 16 h the mixture was evaporated to dryness (65 °C / 15 mbar). 
The resulting residue was taken up in CH2Cl2 (20 mL) and filtered through Celite®, washing well 
with CHCl3. The filtrate was evaporated to dryness and pumped to remove residual DMF. 
Chromatographic processing of the residue (20 g Strata® SI-1 cartridge; 1 : 49.5 : 49.5 
Et2O/CH2Cl2/light petroleum) afford 37 (461 mg, 88%) as a colourless solid. 1H NMR (300 MHz, 
CDCl3) δ 5.06 (s, 2H), 5.13 (s, 2H), 6.59–6.66 (m, 3H), 7.19–7.24 (m, 1H), 7.31–7.46 (m, 5H), 
7.57–7.62 (AAʹBBʹ m, 2H), 7.89–7.92 (AAʹBBʹ m, 2H), 10.03 (s, 1H). 13C NMR (75 MHz, CDCl3) 
δ 69.0 (CH2), 69.9 (CH2), 102.2 (CH), 107.3 (CH), 107.5 (CH), 127.3 (2×CH), 127.4 (2×CH), 
127.9 (CH), 128.5 (2×CH), 129.8 (2×CH), 130.0 (CH), 135.8 (C), 136.8 (C), 143.8 (C), 159.5 (C), 
160.0 (C), 191.7 (CH).
4-((3-((2-Fluorobenzyl)oxy)phenoxy)methyl)benzaldehyde (38). Following the 
procedure for 37, phenol 26 (333 mg, 1.53 mmol) was alkylated to give 38 (317 mg, 62%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 5.12 (s, 2H), 5.14 (s, 2H), 6.58–6.66 (m, 3H), 7.08 
(ddd, J = 9.9, 8.4 and 1.3 Hz, 1H), 7.16 (td, J = 7.5 and 1.2, 1H), 7.18–7.24 (m, 1H), 7.28–7.36 
(m, 1H), 7.47–7.52 (m, 1H), 7.57–7.61 (AAʹBBʹ m, 2H), 7.88–7.92 (AAʹBBʹ m, 2H), 10.03 (s, 
1H). 13C NMR (75 MHz, CDCl3) δ 63.8 (d, J = 4.5 Hz, CH2), 69.3 (CH2), 102.3 (CH), 107.6 (CH), 
107.7 (CH), 115.4 (d, J = 21.0 Hz, CH), 124.1 (d, J = 14.3 Hz, C), 124.3 (d, J = 3.7 Hz, CH), 127.5 
(2×CH), 129.77 (CH), 129.84 (d, J = 4.1, CH), 130.1 (2×CH), 130.2 (CH), 136.0 (C), 144.0 (C), 
159.7 (C), 159.9 (C), 160.5 (d, J = 246.9 Hz, C), 191.9 (CH). 19F NMR (282 MHz, CDCl3) δ –
118.6.
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4-((3-((3-Fluorobenzyl)oxy)phenoxy)methyl)benzaldehyde (39). Following the 
procedure for 37, phenol 27 (325 mg, 1.49 mmol) was alkylated to give 39 (322 mg, 64%) as a 
colourless solid. 1H NMR (400 MHz, CDCl3) δ 5.04 (s, 2H), 5.13 (s, 2H), 6.59–6.62 (m, 3H), 
7.99–7.04 (m, 1H), 7.13–7.23 (m, 3H), 7.34 (td, J = 7.9 and 5.8 Hz, 1H), 7.57–7.61 (AAʹBBʹ m, 
2H), 7.89–7.92 (AAʹBBʹ m, 2H), 10.03 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 69.3 (d, J = 2.0 
Hz, CH2), 69.4 (CH2), 102.6 (CH), 107.7 (CH), 107.8 (CH), 114.3 (d, J = 22.1 Hz, CH), 114.9 (d, 
J = 21.2 Hz, CH), 122.8 (d, J = 2.9 Hz, CH), 127.5 (2×CH), 130.1 (2×CH), 130.20 (d, J = 8.1, 
CH), 130.1 (CH), 136.1 (C), 139.7 (d, J = 7.3 Hz, C), 144.0 (C), 159.8 (C), 159.9 (C), 163.1 (d, J 
= 246.2 Hz, C), 191.8 (CH). 19F NMR (376 MHz, CDCl3) δ –112.6.
4-((3-((4-Fluorobenzyl)oxy)phenoxy)methyl)benzaldehyde (40). Following the 
procedure for 37, phenol 28 (325 mg, 1.49 mmol) was alkylated to give 40 (388 mg, 77%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 5.00 (s, 2H), 5.13 (s, 2H), 6.58–6.63 (m, 3H), 
7.03–7.11 (m, 2H), 7.17–7.24 (m, 1H), 7.36–7.43 (m, 2H), 7.56–7.62 (AAʹBBʹ m, 2H), 7.88–7.92 
(AAʹBBʹ m, 2H), 10.02 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 69.1 (CH2), 69.2 (CH2), 102.3 (CH), 
107.4 (CH), 107.6 (CH), 115.4 (d, J = 21.0 Hz, 2×CH), 127.4 (2×CH), 129.3 (d, J = 7.7 Hz, 2×CH), 
129.9 (2×CH), 130.1 (CH), 132.6 (d, J = 3.3 Hz, C), 135.9 (C), 143.8 (C), 159.6 (C), 159.9 (C), 
162.4 (d, J = 247 Hz, C), 191.7 (CH). 19F NMR (282 MHz, CDCl3) δ –113.9.
4-((3-((2-Chlorobenzyl)oxy)phenoxy)methyl)benzaldehyde (41). Following the 
procedure for 37, phenol 29 (352 mg, 1.50 mmol) was alkylated to give 41 (374 mg, 71%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 5.14 (s, 2H), 5.15 (s, 2H), 6.59–6.66 (m, 3H), 
7.19–7.32 (m, 3H), 7.31–7.43 (m, 1H), 7.53–7.56 (m, 1H), 7.57–7.61 (AAʹBBʹ m, 2H), 7.88–7.92 
(AAʹBBʹ m, 2H), 10.03 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 67.2 (CH2), 69.3 (CH2), 102.3 (CH), 
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107.6 (CH), 107.8 (CH), 127.0 (CH), 127.5 (2×CH), 128.9 (CH), 129.1 (CH), 129.4 (CH), 130.1 
(2×CH), 130.2 (CH), 132.6 (C), 134.6 (C), 136.0 (C), 144.0 (C), 159.7 (C), 159.9 (C), 191.9 (CH).
4-((3-((3-Chlorobenzyl)oxy)phenoxy)methyl)benzaldehyde (42). Following the 
procedure for 37, phenol 30 (348 mg, 1.48 mmol) was alkylated to give 42 (286 mg, 55%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 5.02 (s, 2H), 5.13 (s, 2H), 6.58–6.62 (m, 3H), 
7.17–7.23 (m, 1H), 7.27–7.34 (m, 3H), 7.41–7.44 (m, 1H), 7.57–7.61 (AAʹBBʹ m, 2H), 7.88–7.92 
(AAʹBBʹ m, 2H), 10.03 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 69.1 (CH2), 69.2 (CH2), 102.3 (CH), 
107.6 (2×CH), 125.4 (CH), 127.39 (CH), 127.44 (2×CH), 128.1 (CH), 129.9 (CH), 130.0 (2×CH), 
130.2 (CH), 134.5 (C), 136.0 (C), 139.0 (C), 143.9 (C), 159.6 (C), 159.8 (C), 191.8 (CH).
4-((3-((4-Chlorobenzyl)oxy)phenoxy)methyl)benzaldehyde (43). Following the 
procedure for 37, phenol 31 (331 mg, 1.41 mmol) was alkylated to give 43 (476 mg, 96%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 5.01 (s, 2H), 5.13 (s, 2H), 6.58–6.61 (m, 3H), 
7.17–7.23 (m, 1H), 7.35 (app. s, 4H), 7.56–7.61 (AAʹBBʹ m, 2H), 7.88–7.92 (AAʹBBʹ m, 2H), 
10.03 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 69.18 (CH2), 69.20 (CH2), 102.3 (CH), 107.5 (CH), 
107.6 (CH), 127.4 (2×CH), 128.74 (2×CH), 128.78 (2×CH), 130.0 (2×CH), 130.1 (CH), 133.7 
(C), 135.4 (C), 135.9 (C), 143.9 (C), 159.6 (C), 159.8 (C), 191.8 (CH).
4-((3-((4-Methoxybenzyl)oxy)phenoxy)methyl)benzaldehyde (44). Following the 
procedure for 37, phenol 32 (250 mg, 1.09 mmol) was alkylated to give 44 (256 mg, 68%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 3.82 (s, 3H), 4.97 (s, 2H), 5.13 (s, 2H), 6.56–6.64 
(m, 3H), 6.89–6.94 (AAʹBBʹ m, 2H), 7.17–7.22 (m, 1H), 7.31–7.37 (AAʹBBʹ m, 2H), 7.56–7.61 
(AAʹBBʹ m, 2H), 7.88–7.92 (AAʹBBʹ m, 2H), 10.02 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 55.4 
(CH3), 69.3 (CH2), 70 (CH2), 102.4 (CH), 107.4 (CH), 107.8 (CH), 114.2 (2×CH), 127.6 (2×CH), 
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129.0 (C), 129.4 (2×CH), 130.2 (3×CH), 136.1 (C), 144.1 (C), 159.6 (C), 159.7 (C), 160.3 (C), 
192.0 (CH).
4-((3-((4-Formylbenzyl)oxy)phenoxy)methyl)benzonitrile (45). Following the 
procedure for 37, phenol 33 (357 mg, 1.59 mmol) was alkylated to give 45 (520 mg, 95%) as a 
colourless solid. 1H NMR (300 MHz, CDCl3) δ 5.01 (s, 2H), 5.13 (s, 2H), 6.57–6.30 (m, 3H), 
7.17–7.25 (m, 1H), 7.51–7.55 (AAʹBBʹ m, 2H), 7.56–7.61 (AAʹBBʹ m, 2H), 7.65–7.69 (AAʹBBʹ 
m, 2H), 7.88–7.92 (AAʹBBʹ m, 2H), 10.02 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 68.9 (CH2), 69.2 
(CH2), 102.3 (CH), 107.5 (CH), 107.7 (CH), 111.6 (C), 118.7 (C), 127.4 (2×CH), 127.5 (2×CH), 
130.0 (2×CH), 130.2 (CH), 132.3 (2×CH), 135.9 (C), 142.3 (C), 143.8 (C), 159.4 (C), 159.6 (C), 
191.8 (CH).
4-((3-(Benzylthio)phenoxy)methyl)benzaldehyde (46). Following the procedure for 22, 
4-(bromomethyl)benzaldehyde (301 mg, 1.51 mmol) and phenol 34 (336 mg, 1.55 mmol) gave 46 
(401 mg, 79%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 4.11 (s, 2H), 5.07 (s, 2H), 6.78 
(ddd, J = 8.3, 2.5 and 0.8 Hz, 1H), 6.89 (app. t, J = 2.1 Hz, 1H), 6.94 (ddd, J = 7.7, 1.6 and 0.9 Hz, 
1H), 7.18 (t, J = 8.0 Hz, 1H), 7.22–7.31 (m, 5H), 7.55–7.58 (AAʹBBʹ m, 2H), 7.89–7.91 (AAʹBBʹ 
m, 2H), 10.03 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 38.9 (CH2), 69.3 (CH2), 113.1 (CH), 115.8 
(CH), 122.4 (CH), 127.4 (CH), 127.6 (2×CH), 128.7 (2×CH), 129.0 (2×CH), 129.9 (CH), 130.2 
(2×CH), 136.1 (C), 137.4 (C), 138.2 (C), 143.9 (C), 158.6 (C), 191.9 (CH). 
4-((3-((4-Fluorobenzyl)thio)phenoxy)methyl)benzaldehyde (47). Following the 
procedure for 22, 4-(bromomethyl)benzaldehyde (301 mg, 1.51 mmol) and phenol 35 (398 mg, 
1.70 mmol) gave 47 (495 mg, 93%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 4.07 (s, 2H), 
5.09 (s, 2H), 6.79 (ddd, J = 8.3, 2.5 and 0.8 Hz, 1H), 6.88 (app. t, J = 2.1 Hz, 1H), 6.92 (ddd, J = 
7.7, 1.7 and 0.9 Hz, 1H), 6.93–6.99 (m, 2H), 7.19 (t, J = 8.0 Hz, 1H), 7.21–7.26 (m, 2H), 7.55–
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7.58 (AAʹBBʹ m, 2H), 7.89–7.92 (AAʹBBʹ m, 2H), 10.03 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 
38.1 (CH2), 69.3 (CH2), 113.1 (CH), 115.4 (d, J = 21.5 Hz, 2×CH), 116.0 (CH), 122.6 (CH), 127.5 
(2×CH), 129.9 (CH), 130.1 (2×CH), 130.4 (d, J = 8.1 Hz, 2×CH), 133.1 (d, J = 3.2 Hz, C), 136.1 
(C), 137.7 (C), 158.6 (C), 162.1 (d, J = 245.8 Hz, C), 191.9 (CH). 19F NMR (376 MHz, CDCl3) δ 
–115.2. 
4-((3-((4-Chlorobenzyl)thio)phenoxy)methyl)benzaldehyde (48). Following the 
procedure for 22, 4-(bromomethyl)benzaldehyde (300 mg, 1.51 mmol) and phenol 36 (423 mg, 
1.69 mmol) gave 48 (468 mg, 84%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 4.05 (s, 2H), 
5.07 (s, 2H), 6.79 (ddd, J = 8.3, 2.5 and 0.8 Hz, 1H), 6.86 (app. t, J = 2.1 Hz, 1H), 6.92 (ddd, J = 
7.7, 1.6 and 0.9 Hz, 1H), 7.15–7.26 (m, 5H), 7.55–7.58 (AAʹBBʹ m, 2H), 7.89–7.91 (AAʹBBʹ m, 
2H), 10.03 (s, 1H).. 13C NMR (101 MHz, CDCl3) δ 38.1 (CH2), 69.2 (CH2), 113.2 (CH), 116.1 
(CH), 122.7 (CH), 127.5 (2×CH), 128.7 (2×CH), 129.9 (CH), 130.0 (2×CH), 130.2 (2×CH), 133.0 
(C), 136.0 (C), 136.1 (C), 137.4 (C), 143.7 (C), 158.6 (C), 191.8 (CH).
(R)-(1-(4-((3-(Benzyloxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol (49). To a 
stirred solution of 37 (254 mg, 797 µmol) and (R)-prolinol (170 mg, 1.68 mmol) in anhydrous 
THF (15 mL) under argon was added NaBH(OAc)3 (347 mg, 1.64 mol). The mixture was 
sonicated, at ambient temperature for 3 h. A further portion of NaBH(OAc)3 (214 mg, 1.01 mmol) 
was then added and sonication of the turbid mixture continued for 40 min. The mixture was stirred 
for 12 h, then diluted with 2 M NaOH (aq) (40 mL), vortexing thoroughly, and extracted with 
CHCl3 (250 mL). The extract was dried (MgSO4), evaporated and the residue processed 
chromatographically (20 g Strata® SI-1 cartridge; 2.5% MeOH/CHCl3). Target material eluted 
first, with N-acetylprolinol55 overlapping in tail fractions. Fractions containing clean target 
material were combined and evaporated to afford 49 (225 mg, 70%) as a colourless oil that became 
Page 47 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
an amorphous solid on standing. 1H NMR (400 MHz, CDCl3) δ 1.66–1.75 (m, 2H), 1.83–2.00 (m, 
2H), 2.30 (td, J = 9.3 and 7.5 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.72–2.77 (m, 1H), 2.97–3.01 (m, 
1H), 3.38 (d, J = 13.1 Hz, 1H), 3.44 (dd, J = 10.8 and 2.1 Hz, 1H), 3.67 (dd, J = 10.7 and 3.5 Hz, 
1H), 3.98 (d, J = 13.1 Hz, 1H), 5.02 (s, 2H), 5.05 (s, 2H), 6.59–6.62 (m, 2H), 6.64 (t, J = 2.2 Hz, 
1H), 7.17–7.21 (m, 1H), 7.31–7.35 (m, 3H), 7.37–7.45 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 
23.5 (CH2), 27.9 (CH2), 54.5 (CH2), 58.4 (CH2), 62.1 (CH2), 64.5 (CH), 69.9 (CH2), 70.1 (CH2), 
102.4 (CH), 107.5 (2×CH), 127.5 (2×CH), 127.6 (2×CH), 128.0 (CH), 128.6 (2×CH), 128.9 
(2×CH), 130.0 (CH), 135.8 (C), 137.1 (C), 139.2 (C), 160.2 (2×C). ESI-HRMS [M + H]+ calcd for 
C26H30NO3+, 404.2220; found, 404.2203. HPLC: Method (A) tR 4.56 min (97.7%). [Tail fractions 
from the chromatographic isolation of the product were combined separately to afford a second 
batch (76.5 mg) of 53 contaminated with 12 mol% N-acetylprolinol, giving a total target material 
recovery of 93%.]
(R)-(1-(4-((3-((2-Fluorobenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(50). Following the procedure for 49, aldehyde 38 (261 mg, 776 µmol) afforded 50 (226 mg, 69%) 
as a colourless oil that became an amorphous solid on standing. 1H NMR (400 MHz, CDCl3) δ 
1.65–1.76 (m, 2H), 1.80–1.99 (m, 2H), 2.30 (td, J = 9.2 and 7.6 Hz, 1H), 2.50–3.00 (br. s, 1H), 
2.72–2.77 (m, 1H), 2.96–3.01 (m, 1H), 3.38 (d, J = 13.1 Hz, 1H), 3.44 (dd, J = 10.8 and 2.1 Hz, 
1H), 3.67 (dd, J = 10.8 and 3.5 Hz, 1H), 3.98 (d, J = 13.1 Hz, 1H), 5.03 (s, 2H), 5.12 (s, 2H), 6.60–
6.63 (m, 2H), 6.65 (t, J = 2.3 Hz, 1H), 7.09 (ddd, J = 9.9, 8.4 and 1.3 Hz, 1H), 7.16 (td, J = 7.5 and 
1.2, 1H), 7.20 (t, J = 8.2, 1H), 7.21–7.23 (m, 3H), 7.37–7.40 (AAʹBBʹ m, 2H), 7.48–7.53 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 23.5 (CH2), 27.9 (CH2), 54.5 (CH2), 58.4 (CH2), 62.0 (CH2), 63.8 
(d, J = 4.4 Hz, CH2), 64.5 (CH), 70.0 (CH2), 102.4 (CH), 107.5 (CH), 107.8 (CH), 115.4 (d, J = 
21.2 Hz, CH), 124.27 (d, J = ca.14 Hz, C), 124.30 (d, J = 3.6 Hz, CH), 127.7 (2×CH), 129.0 
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(2×CH), 129.7 (d, J = 8.7 Hz, CH), 129.8 (d, J = 4.1 Hz, CH), 130.0 (CH), 135.8 (C), 139.3 (C), 
159.9 (C), 160.2 (C), 160.5 (d, J = 246.9 Hz, C). 19F NMR (376 MHz, CDCl3) δ −118.6. ESI-
HRMS [M + H]+ calcd for C26H29FNO3+, 422.2126 found, 422.2106. HPLC: Method (A) tR 4.62 
min (97.0%).
(R)-(1-(4-((3-((3-Fluorobenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(51). Following the procedure for 49, aldehyde 39 (258 mg, 768 µmol) afforded 51 (185 mg, 57%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.64–1.76 (m, 2H), 1.80–1.99 (m, 2H), 2.30 (td, 
J = 9.3 and 7.5 Hz, 1H), 2.40–2.90 (br. s, 1H), 2.72–2.77 (m, 1H), 2.96–3.01 (m, 1H), 3.38 (d, J = 
13.1 Hz, 1H), 3.44 (dd, J = 10.7 and 1.8 Hz, 1H), 3.67 (dd, J = 10.8 and 3.5 Hz, 1H), 3.98 (d, J = 
13.1 Hz, 1H), 5.02 (s, 2H), 5.04 (s, 2H), 6.57–6.63 (m, 3H), 6.98–7.04 (m, 1H), 7.13–7.21 (m, 
3H), 7.30–7.40 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 23.5 (CH2), 27.9 (CH2), 54.6 (CH2), 58.4 
(CH2), 62.1 (CH2), 64.5 (CH), 69.3 (CH2), 70.0 (CH2), 102.5 (CH), 107.5 (CH), 107.8 (CH), 114.3 
(d, J = 21.9 Hz, CH), 114.8 (d, J = 21.2 Hz, CH), 122.8 (d, J = 2.9 Hz, CH), 127.7 (2×CH), 129.0 
(2×CH), 130.1 (CH), 130.2 (d, J = 8.2 Hz, CH), 135.8 (C), 139.3 (C), 139.8 (d, J = 7.3 Hz, C), 
159.9 (C), 160.2 (C), 163.1 (d, J = 246.1 Hz, C). 19F NMR (376 MHz, CDCl3) δ −112.7. ESI-
HRMS [M + H]+ calcd for C26H29FNO3+, 422.2126 found, 422.2106. HPLC: Method (A) tR 4.67 
min (> 99%).
(R)-(1-(4-((3-((4-Fluorobenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(52). Following the procedure for 49, aldehyde 40 (263 mg, 783 µmol) afforded 52 (239 mg, 73%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.66–1.75 (m, 2H), 1.80–1.99 (m, 2H), 2.30 (td, 
J = 9.3 and 7.5 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.72–2.77 (m, 1H), 2.96–3.01 (m, 1H), 3.38 (d, J = 
13.1 Hz, 1H), 3.44 (dd, J = 10.8 and 2.1 Hz, 1H), 3.67 (dd, J = 10.8 and 3.5 Hz, 1H), 3.98 (d, J = 
13.1 Hz, 1H), 5.00 (s, 2H), 5.02 (s, 2H), 6.57–6.62 (m, 3H), 7.04–7.10 (m, 2H), 7.17–7.22 (m, 
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1H), 7.30–7.34 (AAʹBBʹ m, 2H), 7.37–7.42 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 23.5 (CH2), 
27.9 (CH2), 54.5 (CH2), 58.4 (CH2), 62.1 (CH2), 64.5 (CH), 69.4 (CH2), 70 (CH2), 102.5 (CH), 
107.5 (CH), 107.6 (CH), 115.5 (d, J = 21.5 Hz, 2×CH), 127.6 (2×CH), 129.0 (2×CH), 129.3 (d, J 
= 8.2 Hz, 2×CH), 130.0 (CH), 132.9 (d, J = 2.9 Hz, C), 135.8 (C), 139.3 (C), 160.0 (C), 160.2 (C), 
162.5 (d, J = 246.1 Hz, C). 19F NMR (376 MHz, CDCl3) δ –114.27. ESI-HRMS [M + H]+ calcd 
for C26H29FNO3+, 422.2126; found, 422.2105. HPLC: Method (A) tR 4.56 min (> 99%).
(R)-(1-(4-((3-((2-Chlorobenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(53). Following the procedure for 49, aldehyde 41 (270 mg, 765 µmol) afforded 53 (196 mg, 58%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.64–1.76 (m, 2H), 1.80–1.99 (m, 2H), 2.29 (td, 
J = 9.3 and 7.6 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.72–2.77 (m, 1H), 2.96–3.01 (m, 1H), 3.37 (d, J = 
13.1 Hz, 1H), 3.44 (dd, J = 10.7 and 1.7 Hz, 1H), 3.67 (dd, J = 10.7 and 3.5 Hz, 1H), 3.98 (d, J = 
13.1 Hz, 1H), 5.03 (s, 2H), 5.15 (s, 2H), 6.60–6.32 (m, 2H), 6.65 (t, J = 2.2 Hz, 1H), 7.18–7.22 
(m, 1H), 7.24–7.29 (m, 2H), 7.30–7.33 (AAʹBBʹ m, 2H), 7.37–7.41 (m overlapping AAʹBBʹ m, 
3H), 7.54–7.57 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 23.5 (CH2), 27.9 (CH2), 54.5 (CH2), 58.4 
(CH2), 62.0 (CH2), 64.5 (CH), 67.3 (CH2), 70.0 (CH2), 102.5 (CH), 107.6 (CH), 107.7 (CH), 127.0 
(CH), 127.7 (2×CH), 128.9 (CH), 128.96 (2×CH), 128.99 (CH), 129.4 (CH), 130.0 (CH), 132.6 
(C), 134.8 (C), 135.8 (C), 139.3 (C), 159.9 (C), 160.2 (C). ESI-HRMS [M + H]+ calcd for 
C26H29ClNO3+, 438.1831 found, 438.1830. HPLC: Method (A) tR 5.00 min (> 99%).
(R)-(1-(4-((3-((3-Chlorobenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(54). Following the procedure for 49, aldehyde 42 (253 mg, 718 µmol) afforded 54 (158 mg, 50%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.63–1.77 (m, 2H), 1.79–2.01 (m, 2H), 2.30 (td, 
J = 9.2 and 7.5 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.71–2.78 (m, 1H), 2.95–3.02 (m, 1H), 3.38 (d, J = 
13.1 Hz, 1H), 3.44 (dd, J = 10.8 and 1.9 Hz, 1H), 3.67 (dd, J = 10.7 and 3.5 Hz, 1H), 3.98 (d, J = 
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13.1 Hz, 1H), 5.01 (s, 2H), 5.02 (s, 2H), 6.56–6.63 (m, 3H), 7.17–7.22 (m, 1H), 7.28–7.34 (m, 
5H), 7.36–7.40 (AAʹBBʹ m, 2H), 7.42–7.44 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 23.6 (CH2), 
27.9 (CH2), 54.6 (CH2), 58.4 (CH2), 62.0 (CH2), 64.5 (CH), 69.3 (CH2), 70.0 (CH2), 102.5 (CH), 
107.5 (CH), 107.8 (CH), 125.4 (CH), 127.5 (CH), 127.7 (2×CH), 128.2 (CH), 129.0 (2×CH), 129.9 
(CH), 130.1 (CH), 134.6 (C), 135.8 (C), 139.2 (C), 139.4 (C), 159.9 (C), 160.2 (C). ESI-HRMS 
[M + H]+ calcd for C26H29ClNO3+, 438.1831 found, 438.1808. HPLC: Method (A) tR 5.03 min (> 
99%).
(R)-(1-(4-((3-((4-Chlorobenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(55). Following the procedure for 49, aldehyde 43 (267 mg, 757 µmol) afforded 55 (286 mg, 86%) 
as a colourless oil that became an amorphous solid on standing. 1H NMR (400 MHz, CDCl3) δ 
1.66–1.74 (m, 2H), 1.81–2.00 (m, 2H), 2.30 (td, J = 9.3 and 7.5 Hz, 1H), 2.60–2.95 (br. s, 1H), 
2.72–2.77 (m, 1H), 2.97–3.01 (m, 1H), 3.38 (d, J = 13.1 Hz, 1H), 3.45 (dd, J = 10.8 and 2.0 Hz, 
1H), 3.67 (dd, J = 10.7 and 3.5 Hz, 1H), 3.98 (d, J = 13.1 Hz, 1H), 5.00 (s, 2H), 5.02 (s, 2H), 6.58 
(dd, J = 8.2, 2.3 and 0.9 Hz, 1H), 6.60–6.63 (m, 2H), 7.17–7.22 (m, 1H), 7.30–7.41 (m, 8H). 13C 
NMR (75 MHz, CDCl3) δ 23.5 (CH2), 27.8 (CH2), 54.5 (CH2), 58.3 (CH2), 61.9 (CH2), 64.4 (CH), 
69.2 (CH2), 69.9 (CH2), 102.3 (CH), 107.4 (CH), 107.6 (CH), 127.7 (2×CH), 128.78 (2×CH), 
128.82 (2×CH), 129.0 (2×CH), 130.0 (CH), 133.8 (C), 135.5 (C), 135.7 (C), 139.3 (C), 159.8 (C), 
160.1 (C). ESI-HRMS [M + H]+ calcd for C26H29ClNO3+, 438.1831; found, 438.1808. HPLC: 
Method (A) tR 5.15 min (97.8%).
(R)-(1-(4-((3-((4-methoxybenzyl)oxy)phenoxy)methyl)benzyl)pyrrolidin-2-
yl)methanol (56). Following the procedure for 49, aldehyde 44 (256 mg, 735 µmol) afforded 56 
(266 mg, 84%) as a colourless oil that became an amorphous solid on standing. 1H NMR (300 
MHz, CDCl3) δ 1.65–1.75 (m, 2H), 1.79–2.01 (m, 2H), 2.30 (td, J = 9.2 and 7.6 Hz, 1H), 2.50–
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3.00 (br. s, 1H), 2.71–2.77 (m, 1H), 2.95–3.02 (m, 1H), 3.38 (d, J = 13.1 Hz, 1H), 3.44 (dd, J = 
10.8 and 2.1 Hz, 1H), 3.67 (dd, J = 10.8 and 3.5 Hz, 1H), 3.82 (s, 3H), 3.98 (d, J = 13.1 Hz, 1H), 
4.96 (s, 2H), 5.02 (s, 2H), 6.58–6.64 (m, 3H), 6.90–6.94 (AAʹBBʹ m, 2H), 7.19 (t, J = 8.2 Hz, 1H), 
7.31–7.40 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 23.5 (CH2), 27.8 (CH2), 54.5 (CH2), 55.4 (CH3), 
58.3 (CH2), 61.9 (CH2), 64.4 (CH), 69.86 (CH2), 69.88 (CH2), 102.3 (CH), 107.4 (CH), 107.5 
(CH), 114.1 (2×CH), 127.7 (2×CH), 128.97 (2×CH), 129.01 (C), 129.3 (2×CH), 130.0 (CH), 135.8 
(C), 139.2 (C), 159.5 (C), 160.1 (C), 160.2 (C). ESI-HRMS [M + H]+ calcd for C27H32NO4+, 
434.2326; found, 434.2304. HPLC: Method (A) tR 4.61 min (97.5%).
(R)-4-((3-((4-((2-(hydroxymethyl)pyrrolidin-1-
yl)methyl)benzyl)oxy)phenoxy)methyl)benzonitrile (57). Following the procedure for 49, 
aldehyde 45 (264 mg, 768 µmol) afforded 57 (124 mg, 38%) as a colourless oil that became an 
amorphous solid on standing. 1H NMR (400 MHz, CDCl3) δ 1.65–1.76 (m, 2H), 1.80–1.99 (m, 
2H), 2.30 (td, J = 9.3 and 7.5 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.72–2.77 (m, 1H), 2.96–3.01 (m, 
1H), 3.38 (d, J = 13.1 Hz, 1H), 3.43 (dd, J = 10.8 and 2.0 Hz, 1H), 3.66 (dd, J = 10.8 and 3.5 Hz, 
1H), 3.97 (d, J = 13.1 Hz, 1H), 5.02 (s, 2H), 5.10 (s, 2H), 6.56 (ddd, J = 8.2, 2.4 and 0.8 Hz, 1H), 
6.60 (t, J = 2.2 Hz, 1H), 6.62 (ddd, J = 8.2, 2.4 and 0.8 Hz, 1H), 7.18–7.22 (m, 1H), 7.31–7.39 
(tight AAʹBBʹ m, 4H), 7.52–7.54 (AAʹBBʹ m, 2H), 7.66–7.69 (AAʹBBʹ m, 2H). 13C NMR (101 
MHz, CDCl3) δ 23.5 (CH2), 27.8 (CH2), 54.5 (CH2), 58.4 (CH2), 62.0 (CH2), 64.4 (CH), 69.0 
(CH2), 70.0 (CH2), 102.5 (CH), 107.4 (CH), 107.9 (CH), 111.7 (C), 118.6 (C), 127.55 (2×CH), 
127.58 (2×CH), 128.9 (2×CH), 130.1 (CH), 132.4 (2×CH), 135.6 (C), 139.4 (C), 142.5 (C), 159.5 
(C), 160.2 (C). ESI-HRMS [M + H]+ calcd for C27H29N2O3+, 429.2173 found, 429.2152. HPLC: 
Method (A) tR 4.25 min (99.8%).
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(R)-(1-(4-((3-(Benzylthio)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol (58). 
Following the procedure for 18, aldehyde 46 (401 mg, 1.20 mmol) afforded 58 (477 mg, 95%) as 
a colourless oil that solidified on standing. 1H NMR (400 MHz, CDCl3) δ 1.65–1.76 (m, 2H), 1.81–
2.00 (m, 2H), 2.30 (td, J = 9.3 and 7.5 Hz, 1H), 2.50–3.00 (br. s, 1H), 2.72–2.77 (m, 1H), 2.96–
3.01 (m, 1H), 3.38 (d, J = 13.1 Hz, 1H), 3.45 (dd, J = 10.8 and 1.8 Hz, 1H), 3.67 (dd, J = 10.7 and 
3.5 Hz, 1H), 3.98 (d, J = 13.1 Hz, 1H), 4.11 (s, 2H), 4.97 (s, 2H), 6.80 (dd, J = 8.3, 2.3 and 0.7 Hz, 
1H), 6.91–6.93 (m, 2H), 7.17 (app. t, J = 8.2 Hz, 1H), 7.22–7.38 (m, 9H). 13C NMR (101 MHz, 
CDCl3) δ 23.6 (CH2), 27.9 (CH2), 38.9 (CH2), 54.6 (CH2), 58.3 (CH2), 61.9 (CH2), 64.4 (CH), 69.9 
(CH2), 113.1 (CH), 115.8 (CH), 122.1 (CH), 127.3 (CH), 127.7 (2×CH), 128.6 (2×CH), 128.9 
(2×CH), 129.0 (2×CH), 129.8 (CH), 135.6 (C), 137.4 (C), 137.9 (C), 139.4 (C), 159.0 (C). ESI-
HRMS [M + H]+ calcd for C26H30NO2S+, 420.1992; found, 420.1995. HPLC: Method (A) tR 4.61 
min (>99%).
(R)-(1-(4-((3-((4-Fluorobenzyl)thio)phenoxy)methyl)benzyl)pyrrolidin-2-yl)methanol 
(59). Following the procedure for 18, aldehyde 47 (487 mg, 1.38 mmol) afforded 59 (471 mg, 
78%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.65–1.73 (m, 2H), 1.80–1.99 (m, 2H), 
2.29 (td, J = 9.3 and 7.5 Hz, 1H), 2.60–2.85 (br m, 1H), 2.71–2.77 (m, 1H), 2.95–3.01 (m, 1H), 
3.37 (d, J = 13.1 Hz, 1H), 3.44 (dd, J = 10.8 and 1.8 Hz, 1H), 3.66 (dd, J = 10.7 and 3.5 Hz, 1H), 
3.97 (d, J = 13.1 Hz, 1H), 4.07 (s, 2H), 4.98 (s, 2H), 6.80 (ddd, J = 8.3, 2.3 and 1.1 Hz, 1H), 6.88–
6.91 (m, 2H), 6.93–6.99 (m, 2H), 7.15–7.19 (m, 1H), 7.21–7.25 (m, 2H), 7.31–7.37 (tight AAʹBBʹ 
m, 4H). 13C NMR (101 MHz, CDCl3) δ 23.6 (CH2), 27.9 (CH2), 38.3 (CH2), 54.6 (CH2), 58.4 
(CH2), 62.0 (CH2), 64.5 (CH), 70.0 (CH2), 113.4 (CH), 115.4 (d, J = 21.5 Hz, 2×CH), 116.3 (CH), 
122.5 (CH), 127.7 (2×CH), 129.0 (2×CH), 129.8 (CH), 130.5 (d, J = 8.1 Hz, 2×CH), 133.3 (d, J = 
2.9 Hz, C), 135.7 (C), 137.5 (C), 139.5 (C), 159.1 (C), 162.2 (d, J = 245.5 Hz, C). 19F NMR (282 
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MHz, CDCl3) δ –115.2. ESI-HRMS [M + H]+ calcd for C26H29FNO2S+, 438.1898; found, 
438.1891. HPLC: Method (A) tR 4.94 min (95.4%).
(R)-(1-(4-((3-((4-Chlorobenzyl)thio)phenoxy)methyl)benzyl)pyrrolidin-2-
yl)methanol (60). Following the procedure for 18, aldehyde 48 (100 mg, 0.260 mmol) afforded 
60 (62 mg, 53%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 1.66–1.74 (m, 2H), 1.80–1.99 
(m, 2H), 2.29 (td, J = 9.3 and 7.5 Hz, 1H), 2.50–2.85 (br m, 1H), 2.72–2.77 (m, 1H), 2.95–3.00 
(m, 1H), 3.38 (d, J = 13.1 Hz, 1H), 3.44 (dd, J = 10.8 and 2.2 Hz, 1H), 3.67 (dd, J = 10.8 and 3.5 
Hz, 1H), 3.98 (d, J = 13.1 Hz, 1H), 4.05 (s, 2H), 4.98 (s, 2H), 6.81 (ddd, J = 8.3, 2.4 and 1.1 Hz, 
1H), 6.88–6.91 (m, 2H), 7.15–7.22 (m, 3H), 7.23–7.26 (m, 2H), 7.31–7.37 (tight AAʹBBʹ m, 4H). 
13C NMR (101 MHz, CDCl3) δ 23.6 (CH2), 27.9 (CH2), 38.4 (CH2), 54.6 (CH2), 58.4 (CH2), 62.0 
(CH2), 64.51 (CH), 70.0 (CH2), 113.5 (CH), 116.4 (CH), 122.6 (CH), 127.7 (2×CH), 128.7 
(2×CH), 129.0 (2×CH), 129.9 (CH), 130.2 (2×CH), 133.1 (C), 135.7 (C), 136.2 (C), 137.2 (C), 
139.5 (C), 159.2 (C). ESI-HRMS [M + H]+ calcd for C26H29ClNO2S+, 454.1602; found, 454.1603. 
HPLC: Method (A) tR 5.27 min (98.8%).
Molecular modeling. An SK2 homology model was constructed in order to provide a 
qualitative understanding of ligand selectivity determinants. The preliminary model was generated 
through the SWISS-MODEL server47-50 by submission of the SK2 sequence and specification of 
the SK1/PF-543 co-crystal structure (4V24 chain A, 1.8 Å resolution)38 as a template. In SK1 a 
regulatory ‘R-loop’ (41 residues) is interposed between strands β9/β10 of the CTD and makes no 
contact with the 3 lipid binding loops that pack to form the J-channel on the opposite face of the 
CTD core β-sandwich. (See supplementary Figure S1 in Adams et al39 for SK1/SK2 sequence 
alignment and definition of loops.) The R-loop in SK2 is substantially longer (156 residues) and, 
in the absence of a suitable template, no attempt was made to model it. Thus, the core of this loop 
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sequence (SK2 residues 345–488 inclusive) was deleted. The implicit assumption, that the R-loop 
does not directly impact on the structure of the J-channel heel and toe regions, was deemed 
reasonable based on the known disposition of the R-loop in SK1 crystal structures. The length of 
the lipid binding loops is identical for SK1 and SK2 and the loops exhibit a high degree of sequence 
conservation: LBL-1 (34 residues), 62% identity; LBL-2 (21 residues), 43% identity; LBL-3 (28 
residues), 61% identity. Very close structural homology observed between the SK2 model output 
from the SWISS-MODEL server and the SK1 template was therefore fully reasonable. 
The model was refined using the protein preparation and refinement tools in the Small 
Molecule Drug Discovery (SMDD) software suite from Schrödinger, LLC. Ramachandran plot 
analysis of the crude model (lacking the R-loop) identified 4 residues (Ser209, Ala523, Thr578, 
Pro579) with outlier φ and ψ angle combinations. These were considered sufficiently remote from 
the J-channel to have little bearing on the quality of the model as starting point for refinement. 
Hydration from the template protein (4V24) was merged into the model together with a J-channel 
ligand, SKi (10), from its co-crystal structure (3VZC, chain A) aligned to the crude model. The 
latter was selected as a suitable J-channel ligand for refinement work because it inhibits both SK1 
and SK2 with little discrimination and because the structure of the SK1 J-channel is conserved 
when bound by PF-543 or SKi. The hydroxymethyl group of PF-543 mimics the 3-OH of Sph 
substrate in engaging Asp308 on helix-α7. In its absence, as with bound SKi, the position of the 
hydroxyl is occupied by a surrogate water, defined as W2 in Figure S3 of Adams et al39. A water 
was therefore inserted into the W2 position of the crude model with SKi. The model was manually 
inspected and waters imported from the 4V24 template that were sterically interdicted were deleted 
or moved to take account of side chain conformations. 
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The C-terminal end of the less strongly conserved LBL-2 was remodelled with a template 
taken from residues 209-PEAQVDDGKLHL-220 in the crystal structure (4WER) of a prokaryotic 
diacylglycerol kinase family protein. These residues correspond to 521-PHARFDDGLVHL-532 
in SK2 and 276-PMGRCAAGVMHL-287 in SK1. In the 4WER structure, the residues in this 
sequence form a well-defined lariat which is highly conserved across related crystal structures 
(2BON, 2JGR, 2P1R, 2QV7, 2QVL, 3S40, 3T5P, 4WRR).  In several of these the lariat hosts a 
non-catalytic metal ion by coordination to an aspartate in a DG motif that is conserved in all the 
structures and also in SK2 but not in SK1. Where present, the metal ion is also coordinated by a 
conserved aspartate on one of two long crossed β-strands that form the key interdomain 
connection. This latter residue (Asp281) is also conserved in SK2 but not conserved in SK1, where 
the cognate residue is Asn151. When the metal ion is absent, a structural water molecule acts as a 
surrogate through hydrogen bonded interactions, as is the case in the 4WER crystal structure. The 
metal ion may have a regulatory role in the prokaryotic enzymes.56,57 At present there is no 
evidence to support a role for non-catalytic metal ion regulatory control over SK2, and we therefore 
modelled the SK2 lariat on the metal-free structure of 4WER.
To refine the model, preparation was undertaken with the SMDD protein preparation 
wizard using default optimisation and restrained minimisation routines. Full OPLS3 force field 
protein minimisation was then undertaken in iterations, initially with SK1-templated Cartesian 
constraints on selected residues lining the interdomain cleft, at the interdomain tip interface of 
LBL-1 and at the hinge of LBL-3. The constraints were defined to restrain interdomain movement 
and to mimic a helix-capping interaction seen in SK1 crystal structures from Arg291 on LBL-
3/helix-α9 (conserved as Arg541 in SK2) to the backbone at the C-terminal end of LBL-1/helix-
α8. The constraints were progressively removed following the initial minimisation with the 
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remodelled LBL-2 loop structure and omitted altogether in the final minimisation. Ramachandran 
plot analysis of the minimsed model identified no residues with outlier φ and ψ angle 
combinations. Standard precision (Glide SP) docking routines within SMDD were employed for 
ligand docking using grids generated with SKi as the binding site identifier. Docked structures 
were then processed with the SMDD Prime refine protein−ligand complex utility using local 
optimisation settings within an 8 Å radius of the ligand. In the case of VT20dd (9), initial ligand 
docking was undertaken with the smaller analogue, (protonated) (S)-2-((3-(4-((4-(3-
(trifluoromethyl)phenyl)thiazol-2-yl)amino)phenyl)-1,2,4-oxadiazol-5-yl)methyl)pyrrolidine-1-
carboximidamide (compound 20l in Childress et al),36 to define a binding mode for the core and 
polar head group of this SK inhibitor chemotype. The ligand in the resulting model was then rebuilt 
using the SMDD build tools and subjected to the SMDD Prime refine protein−ligand complex 
routine.
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Cer, ceramide; CTD, C-terminal domain; HDAC1/2, histone deacetylases 1/2; LBL, lipid binding 
loop; NTD, N-terminal domain; R-loop, regulatory loop; S1P, sphingosine 1-phosphate; SK1, 
sphingosine kinase 1; SK2, sphingosine kinase 2; Sph, sphingosine.
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 Figure 1. The structure of SK1 is shown with bound PF-543 (1; orange surface) (PDB: 4V24). PF-543 
occupies the substrate Sph binding site, formed by the packing of three lipid binding loops (LBL-1 to LBL-3) 
against a β-sandwich core. The nucleotide binding site is shown by superimposition of Mg-ADP (green 
sphere/rose surface) from its separate co-crystal structure (3VZD) with SK1. 
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 Figure 2. J-channel surface detail (mesh) from the PF-543/SK1 co-crystal (PDB: 4V24), highlighting key 
isoform residue differences that likely impact on the J-channel struc-ture of SK2. SK1 residue numbering is 
shown; cognate SK2 residues, where different, are in parenthesis. (Residue color notation: see text.) 
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 Figure 5. Comparison of modelled binding mode for SK2-selective inhibitor 60 with SK1 co-crystal 
structures of PF-543 (1) and SKi (10). Panel (A): 60 (blue stick) docked into SK2 model (red mesh), 
highlighting key contact residues (cyan stick) and ex-panded SK2 J-channel toe surface. Panel (B): PF-543 
(1; orange stick) is shown from its co-crystal structure (4V24) with SK1 (green mesh) and the SK2 model 
surface (red mesh) overlaid from (A); SK1 contact residues are shown (light orange stick) and the 
constrained SK1 J-channel toe surface is evident. Panel (C): As (B), but showing co-crystal structure (3VZD) 
of SKi (10, magenta stick) with SK1 (blue mesh and pink stick key contact residues) superimposed onto the 
SK2 model (red mesh) from panel (A); the heel region adjacent to SK1 Leu302 is consistently less 
compressed in SK1 structures (relative to the SK2 model), whilst the notch surface exhibits some plasticity. 
Panel (D): overlay of (A)–(C) minus the J-channel surface; the chlorine atom of 60 is ac-commodated in SK2 
between Cys588 and Leu506, with rotation of the latter possible whilst the cognate SK1 residue (Leu261) is 
constrained by the packing of adjacent residues. 
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 Figure 6. The J-channel heel is a key determinant of isoform discrimination by SK inhibitors. Panel (A): LBL-
2 and LBL-3 are shown from the co-crystal structure (4V24) of PF-543 (orange stick) with SK1 (green 
ribbon); the corresponding elements from our SK2 homology model (red ribbon) are overlaid, illustrating 
inward movement in LBL-3 leading to heel compression in SK2 by Leu547. Panel (B): Potent unselective 
inhibitor 49 (blue stick) is shown modelled into the SK2 J-channel (red mesh); the J-channel heel surface is 
driven significantly inwards relative to SK1 so that the presence of a sulfonyl group in the ligand (49 --> 19, 
56-fold activity loss) is poorly tolerated by SK2. Panel (C): Inhibitor 49 (magenta stick) is again shown, here 
modelled into the SK1 J-channel (green mesh); the SK1 J-channel heel surface exhibits less compression 
and accommodates a sterically more demanding sulfonyl containing linker more readily (49 --> 19, no 
activity loss; 23 --> 18, 5-fold activity loss). Panel (D): overlay of (B) and (C) minus the J-channel surface. 
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 Figure 7. The J-channel toe is a second key determinant for isoform discrimination by SK inhibitors. A 
comparison of modelled binding modes for the SK2-selective inhibitor (60) is shown here, with the SK2-
docked inhibitor (cyan stick) superimposed onto the SK1-docked inhibitor (magenta stick). With reduced 
plasticity in the SK1 J-channel toe (pink mesh), the sulfur atom of 60 is predicted to be tightly wedged 
against the backbone of helix-α9 (pink ribbon). This generates an unfavourable compression axis (black 
arrow, corresponding to ‘Axis-2’ of Figure 3) that preferentially penalizes binding to SK1. In SK2 the greater 
plasticity of the J-channel toe (cyan mesh) is predicted to allow accommodation of 60 with less compression. 
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 Figure 8. Plasticity in the J-channel toe of SK2 may be exploited to develop SK2-selective inhibitors. Panel 
(A): Compound 60 (blue stick) docked into the SK2 model (red mesh), highlighting key contact residues 
(cyan stick) and two predicted trajectories for possible toe expansion (arrows). Small groups may be 
accommodated between Cys533 and Leu506 (Trajectory-1, hollow ar-row). This is the predicted expansion 
for binding of 55/60, where the fit of the Cl atom is likely made possible largely by rotation in Leu506. 
Larger groups may be accommodated between Cys533 and Phe557 (Trajectory-2, filled arrow) upon rotation 
of these side chains. Panel (B): VT-20dd (9, green stick) docked into the SK2 model (grey mesh), 
highlighting key contact residues (orange stick). Here the ligand is predicted to exploit the second toe 
expansion trajectory. Panel (C): Overlay of (A) and (B) showing the SK2 J-channel surface for docked 60 
(red mesh) and illustrating the two key residue rotations in Cys533 and Phe557 required for Trajectory-2 
expansion (cyan stick --> orange stick positions). Panel (D): ABC294640 (4, orange stick) docked into SK2 
(grey mesh). In this model, the Trajectory-1 expansion is made possible chiefly by rotation of Cys533 rather 
than Leu506, but the space generated by the expansion is underused by the Cl atom. 
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